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Abstract 
Glioma is a cancer derived from transformed glial cells; these tumours are often 
invasive and display a heterogeneous cell population, with various phenotypes. 
Current treatment modalities for glioma are ineffective, with minimal improvement to 
overall patient survival over the last decade. Targeted approaches that take advantage 
of the various biomarkers displayed within glioma are required to deliver therapeutics 
more specifically. Aptamers are short oligonucleotides that conform to unique three 
dimensional structures based on sequence and are able to target molecules 
selectively, in order to deliver therapeutic agents directly to the tumour. 
Aptamers can be selected against whole cells via cell-SELEX, for production of a 
targeting ligand, which may also have the secondary advantage of revealing novel 
biomarkers if the target of the aptamer is elucidated. Previously, the glioblastoma cell 
line U87MG has been utilised in cell-SELEX for aptamer identification, however cell 
lines may not ubiquitously express all biomarkers indicative of glioblastoma. 
Consequently, cell-SELEX using short term cultures from human tissue may produce 
aptamers that target novel biomarkers. As primary cells are only available in small 
numbers, a cell-SELEX procedure was developed that was able to identify aptamers 
using 100 cells. Utilising this procedure, seven novel DNA aptamers were selected to 
short term cultures. Validation studies using oligohistochemistry showed the aptamers 
may interact with a protein on the cell surface. 
DNA aptamers were also identified towards two known biomarkers important for 
gliomagenesis; EGFRvIII and PDE1C. Ten DNA aptamers were isolated towards a 
peptide within the mutated region for EGFRvIII and four aptamers were targeted 
towards the PDE1C protein. Whilst validation studies via Western blot showed no 
aptamer-protein interaction when using the EGFRvIII aptamers, denaturing and native 
Western blots showed positive results displaying 3 bands indicative of PDE1C isoforms. 
PDE1C aptamer targets were pulled out of native cell lysate via an aptoprecipitation 
assay, which showed similar banding patterns to the Western blots. 
The results presented suggest the potential of aptamers to target short term cultures 
and also protein biomarkers that are over-expressed or truncated within glioma. 
Whilst further studies are required to elucidate binding characteristics, these aptamers 
have the potential to assist therapeutic agents become more specific. 
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1.0  Introduction 
A major challenge in the diagnosis and treatment of cancer is the identification of 
molecules that recognise cellular and molecular differences between diseased and 
healthy tissue. With respect to these criteria, aptamers have received high interest 
ever since they were first described in 1990 (Ellington and Szostak, 1990). 
Aptamers, regarded as chemical antibodies, are selected through systematic 
evolution of ligands by exponential enrichment (SELEX); an in vitro process that can 
accommodate various targets such as peptides, proteins and whole cells (Tuerk and 
Gold, 1990). To date, many aptamers have been selected against cancer, such as 
breast, liver and prostate cancer (Lupold et al., 2002, Shangguan et al., 2008, Liu et 
al., 2012). Selective aptamers rely on truncated, defective or overexpressed 
biomarkers observed within disease state for differential recognition from healthy 
tissue. For example, the aptamer HB5 targets human epidermal growth factor 
receptor 2 (HER2), a biomarker specific to breast cancer (Liu et al., 2012). 
Glioma is a cancer of the central nervous system (CNS) originating from neuroglia. 
The utilisation of aptamers to target glioma has been of interest in the last decade, 
with numerous groups selecting aptamers that offer various biomedical 
applications, such as diagnostics and biosensors (Song et al., 2008), therapeutics 
(Bates et al., 2009) including drug delivery (Huang et al., 2009). Although glioma 
only represent a small percentage of cancer incidences, mortality rates are often 
high (Schwartzbaum et al., 2006). Currently, diagnosis involves hospitalisation for 
an invasive biopsy and treatment is non-selective which is usually intolerable in the 
elderly (Brandes et al., 2009, Weller, 2011).  
1.1  Glioma 
1.1.1  Classification and grading of glioma 
Glial cells are the most common cell type within the central nervous system (CNS). 
The transformation of these cells leads to invasive tumours forming in the brain 
called gliomas. Glioma comprises a group of heterogenous tumours derived from 
 3 
 
glial progenitor cells, stem cells or de-differentiated cells that are defined by cell 
lineage, such as ependymal, astrocytic or oligodendrocytic (Ricard et al., 2012). 
Different types of glioma are matched to a grade (I – IV) via the World Health 
Organisation (WHO) classification system (Louis et al., 2007). The grade allocated to 
each tumour type is dependent on histological criteria which corresponds to 
severity (benign grade I – malignant grade IV), facilitates diagnosis and predicts 
prognosis (Louis et al., 2007, Ricard et al., 2012).  
During histological examination, the morphology of the tissue is examined and 
abnormalities representative of glioma are noted (Table 1.1) (Ricard et al., 2012). 
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Table 1.1 – The histological classification of glioma according to The World Health Organisation (WHO), adapted from (Ricard et al., 2012). 
 Grade Histological subtype Phenotype Grading Median 
Survival 
(Years) 
    Differentiation Cell density Nuclear 
atypia 
Mitotic 
activity 
Microvascular 
proliferation 
Necrosis  
As
tr
oc
yt
om
a 
Grade II Diffuse astrocytoma Fibrillary or gemistocytic 
neoplastic astrocytes 
Well differentiated Moderate Occasional Generally 
absent 
Absent Absent 6 - 8 
Grade III Anaplastic 
astrocytoma 
Same as grade II Regional or diffuse 
anaplasia 
Regionally Present Present Absent Absent 3 
Grade IV Glioblastoma Pleomorphic astrocytic 
tumour cells 
Poor High Marked Marked Prominent Present 1 - 2 
O
lig
od
en
dr
og
lio
m
a 
Grade II Oligodendroglioma Monomorphic cells, 
uniform round nuclei, 
perinuclear halos 
Well differentiated Moderate Possibly 
marked 
Absent or 
occasional 
Not prominent Rare 12 
Grade III Anaplastic 
oligodendroglioma 
Same as grade II Regional or diffuse 
anaplasia 
Increased Marked Prominent Often 
prominent 
Possible 3 - ≥10 
O
lig
oa
st
ro
cy
to
m
a Grade II Oligoastrocytoma Neoplastic glial cells with 
both phenotypes 
Well differentiated Moderate Occasional Rare Absent Absent 6 
Grade III Anaplastic 
oligoastrocytoma 
Same as grade II Anaplasia High Marked High May be present Absent  3 
GMBO = Glioblastoma with Oligodendroglioma component
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The qualitative assessment of mitosis, cellular density, tumour differentiation and the 
presence of blood vessels predict the aggressiveness of the cancer (Louis et al., 2007, 
Ricard et al., 2012). As the grade increases, morphological features observed in glioma 
become more exaggerated (Fig 1.1). Grade I, such as pilocytic glioma present with little 
proliferation, are well differentiated and are generally curable by resection (Louis et 
al., 2007). Grade II, such as diffuse astrocytoma or oligodendroglioma, are infiltrative 
neoplasms with low proliferation which are well differentiated (Louis et al., 2007). 
Associated with grade II tumours are high rates of recurrence, this is caused by the 
infiltrative nature of the tumour in to the surrounding tissue with unpredictable 
growth patterns (Duffau, 2013, Ellenbogen et al., 2013). Anaplastic grade III gliomas 
are malignant neoplasms with abnormal proliferative behaviour that display 
hyperchromatism and pleomorphic cellularity (Engelhard et al., 2002, Reifenberger 
and Collins, 2004, Louis et al., 2007). Grade IV malignant glioma features prominent 
proliferation and evidence of necrosis (Louis et al., 2007). Glioblastoma (GBM), an 
astrocytic grade IV tumour, can arise as a direct transformation from astroglia cells 
(primary or de novo) or indirectly (secondary), progressing from benign grade II 
through to malignant grade IV (Wen and Kesari, 2008). GBM incur high rates of 
recurrence and are often fatal. Glioma stem cells or de-differentiated cells present in 
GBM are liable to genotypic evolution after therapy, resulting in therapeutic resistance 
(Salmaggi et al., 2006, Bao et al., 2006, Schwartzbaum et al., 2006). Many 
characteristics are shared between different histological sub-types, however some are 
specific to tumour type, such as the appearance of perinecrotic palisading in 
glioblastoma (Weller, 2011) (Figure 1.1D).  
 The validity of the WHO classification system has been questioned due to varied 
interobserver reliability (van den Bent, 2010). Morphological classification is subjective 
and is therefore liable to observational error, reducing reproducibility (Ricard et al., 
2012). Efforts in the last decade have been focused towards producing a classification 
system based on molecular aberrations. This would provide a standardised system 
which is more reproducible (further discussed in Section 1.1.3). 
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Figure 1.1- Tissue sections of glioma corresponding to cellular lineage and grade. The tissue 
sections show the morphology of astrocytoma (A-D), oligodendroglioma (E and F) and 
oligoastrocytoma (G-I), which are of differing grade. As the grade increases, the degree of 
abnormal cellularity and nuclear atypia increases. Some characteristics are specific to cell 
lineage due to their phenotype, such as the uniform round cells observed in 
oligodendrogliomas (E and F). Other features are specific to tumour type, such as perinecrotic 
palisading in glioblastoma (D) or the ‘honeycomb’ effect as seen in anaplastic 
oligodendroglioma (F). Figure adapted from (Cavaliere et al., 2005, Salvati et al., 2009, Martens 
et al., 2013) 
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1.1.2  Epidemiology  
Globally collated evidence shows there are several epidemiological factors 
predisposing individuals to glioma, such as sex, age, ethnicity, exposure to radiation 
and inherited mutations (Bondy et al., 2008). Each year there is an estimated 6.3 cases 
of primary brain cancer per 100,000 population worldwide (Bondy et al., 2008), with 
glioma accounting for approximately 80% of all brain tumour cases (Ohgaki, 2009). 
Incidences are higher in developed countries (9.9 cases compared per 100,000 
population) compared to undeveloped countries (5.1 cases per 100,000 population) 
(Ohgaki, 2009). The large variation may be explained by inadequate detection in 
underdeveloped regions or by ethnicity, as Caucasians are twofold more likely to 
develop glioma than people of African or Asian descent (Fan and Pezeshkpour, 1992). 
Nevertheless, this requires further investigation in order to prevent under-observation 
of incidences.  
Males are more likely to develop malignant brain tumours than females, who are more 
likely to develop benign tumours (Ostrom et al., 2013). In the UK during 2010 (Fig 1.2), 
34% of brain, CNS and intracranial tumours were astrocytomas, of which 80% were 
glioblastoma (GBM); a highly aggressive astrocytoma more prevalent in men. 
Worldwide data shows that the majority of GBMs are primary (90%) with a higher 
tendency to develop in men (1.33 male:female ratio) (Ohgaki and Kleihues, 2007, 
Ohgaki and Kleihues, 2005). In contrast to the aggressive malignant primary sub-type, 
secondary tumours are less aggressive with higher incidence in females (0.66 
male:female ratio) (Ohgaki and Kleihues, 2005). Epidemiological information regarding 
glioma in the United Kingdom (UK) has been criticised due to under-recording of cases, 
with records currently lacking detailed information on the incidence of different 
tumour types (Chalmers, 2011). Consequently there is no definitive epidemiological 
data regarding primary or secondary GBM, possibly due to the differential tumour 
genotypes often displaying no phenotypical differences, therefore being histologically 
indistinguishable (Ohgaki and Kleihues, 2007). In addition, Ohgaki observed that the 
majority of GBMs diagnosed in the US are primary or de novo tumours. This is because 
the initial diagnosis is recorded and not the tumour grade where it has progressed 
from grades I to IV, which can happen with secondary GBMs.   
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Figure 1.2- Brain, other CNS and intracranial tumour incidence during 2010 in the United 
Kingdom. Adapted using statistics provided by Cancer Research UK (CRUK, 2014) 
Primary or de novo GBM appear within weeks often without presenting any clinical 
signs, in contrast secondary GBM tumours progress from benign grade I through to 
malignant grade IV GBM (Ohgaki and Kleihues, 2007). Primary GBM mortality rates are 
high in comparison to secondary tumours, with median survival rates of 4.7 months 
and 7.8 months respectively (Ohgaki et al., 2004). The varied clinical features of both 
primary and secondary GBM can be explained by dysregulated signal transduction 
pathways which contribute to gliomagenesis. Mutated epidermal growth factor 
receptor (EGFR) and phosphate and tensin homologue (PTEN) are indicative of primary 
GBM, wereas isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations are indicative of 
secondary GBM (Goodenberger and Jenkins, 2012). Both routes to gliomagenesis may 
also converge to vascular endothelial growth factor (VEGF) mutations for angiogenesis. 
1.1.3  Aetiology 
Indeed, no single mutation will ensure the transformation of a cell from healthy to 
cancerous. Instead a set of mutations must be present to guarantee cancer cell survival 
by preventing apoptosis and enhancing proliferation. In 1940, Hans-Joachim Scherer 
noticed a clear distinction between primary and secondary glioblastoma which was 
based upon clinical presentation (Peiffer and Kleihues, 1999). Unknown to him, 
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differences in clinical presentation was caused by expression of different sets of 
aberrant proteins, which have since been elucidated. Gliomagenesis may occur when 
proteins important to the regulation of cellular pathways become abnormally 
expressed or truncated. Gain and loss of function mutations within proto-oncogenes 
and tumour suppressor genes (TSGs) can be observed throughout each glioma grade; 
however each grade may confer a unique set of mutations in order to become 
biologically immortal.  
1.1.3.1 Tyrosine Receptor Kinases (RTKs) 
The receptor tyrosine kinase (RTK) pathway is activated in 88% of glioma tumours, 
with mutations occurring in the RTK receptor and downstream signalling components. 
RTKs are a superfamily of transmembrane proteins involved in signalling to the cell 
when to proliferate. Upon interacting with growth factors, a conformational change 
results in the activation of kinases within the intracellular domains of the receptor. 
Subsequently, other proteins, such as Ras and phosphoinositide 3-kinase (PI3K) are 
recruited and the cell initiates proliferation. Over-expressed or truncated RTKs, such as 
platelet derived growth factor receptor (PDGFR) and epidermal growth factor receptor 
(EGFR) may result in the dysregulation of cellular proliferation. In addition mutations 
must also be present in TSGs that regulate the activation of downstream mediators, 
such as PTEN, p53 and retinoblastoma protein (Rb). 
EGFR is an RTK that may play an important role in gliomagenesis. Epidermal growth 
factor (EGF) can bind to a homodimer of EGFR resulting in allosteric 
transphosphorylation of the receptor between the intracellular kinase domains (Zhang 
et al., 2006). Downstream mediators are then recruited to the tyrosine kinases and the 
subsequent phosphorylation of the recruited proteins induces proliferative pathways 
and represses anti-apoptotic mechanisms. The most common mutation seen in glioma 
is the amplification of the EGFR gene. Low levels of EGFR repeats are often seen within 
chromosome 7. Higher levels of gene amplification are usually observed when EGFR 
copies exist in extrachromosomal double minutes (dmins) (Vogt et al., 2004). EGFR 
copies can be as high as 100 in extreme cases, which translate to the over-expression 
of EGFR (Lopez-Gines et al., 2010). Glial cells are not capable of producing EGF, 
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however they may produce transforming growth factor alpha (TGF-α), another EGFR 
activator. This growth factor initiates similar effects to EGF and, as both receptor and 
ligand are produced by the cell, an autocrine loop is produced initiating proliferative 
behaviour further (von Bossanyi et al., 1998). The amplification of EGFR is noted to 
occur in 36% of primary glioblastomas and 8% of secondary glioblastomas (Ohgaki et 
al., 2004). A second mutation of EGFR is seen in 75% of cases exhibiting EGFR 
amplification, known as EGFR variant III (EGFRvIII) (Sugawa et al., 1990). 
EGFRvIII is a constitutively active receptor independent of ligand interaction that is co-
expressed with the wild type receptor (EGFRwt) (Ge et al., 2002). A rearrangement of 
the EGFR gene results in the deletion of exons 2-7. The amino acids 6-273, usually 
present in the extracellular domain, are therefore lost producing a truncated EGFR that 
is constantly active (Prigent et al., 1996). Under the influence of growth factor binding, 
EGFRwt dimerises and the intracellular kinase domains become activated (Zhang et al., 
2006). Initially, it was thought that the truncated EGFRvIII did not dimerise and 
propagated intracellular signalling in monomeric form (Chu et al., 1997, Gajadhar et 
al., 2012). The absence of a ligand binding site on the oncogenic protein further 
supported this theory, as the binding site was instrumental for dimerisation. Later 
studies showed monomeric EGFRvIII to have no activity and therefore conferred no 
tumorigenicity, implying the protein must dimerise in order to signal to the cell 
(Kancha et al., 2013). EGFRvIII possesses the ability to either homodimerise with 
another EGFRvIII protein or heterodimerise with the wild type version (Gajadhar et al., 
2012, Luwor et al., 2004). Within the heterologous version, EGFRvIII activates EGFRwt 
independent of its ligand through transphosphorylation, furthering the tumorigenic 
potential of this oncogenic protein (Fan et al., 2013). Post-signal transduction, RTKs are 
normally internalised quickly and ubiquitinated ready to be degraded to prevent 
prolonged signals. The ubiquitin ligase enzyme Cbl is usually recruited to the EGFR 
receptor following signal transduction; however if the Cbl-EGFRvIII interaction is 
perturbed, it can lead to prolonged proliferative signalling. Cbl can internalise the 
EGFRvIII directly, through the phosphorylation of the amino acid Y1045, or indirectly, 
through the adapter protein Grb2 (Davies et al., 2006, Waterman et al., 2002). 
Hypophosphorylation of Y1045 on EGFRvIII leads to poor internalisation and, rather than 
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lysosomal degradation, the receptor is recycled in the cytoplasm and re-expressed on 
the cell surface (Grandal et al., 2007). Poor internalisation of the constantly active 
receptor and improper degradation enhances the oncogenic potential of EGFRvIII, 
leading to prolonged signal transduction and an increased half-life within the cell. 
EGFRvIII is not expressed in non-cancerous cells therefore is a potential target for 
selective therapy to cancer cells. Antibodies have been produced against EGFRvIII, 
however many cross react with the EGFRwt (Gupta et al., 2010).  
Glial cells can produce platelet derived growth factor (PDGF), which is required for 
differentiation of glial cells and also promotes proliferation. PDGFR is produced by the 
dimerisation of PDGFRα and PDGFRβ, either homogenously or heterogeneously 
(Lokker et al., 2002). PDGF and PDGFR (specifically PDGFRα) is overexpressed in low-
grade astrocytomas and oligodendrogliomas, and the PDGFRα genes are amplified in 
10% of secondary glioblastomas (Ohgaki et al., 2004, Karcher et al., 2006). The 
overexpression of both ligand and receptor produces an autocrine loop resulting in 
recurrent proliferation.  
One feature almost exclusive to primary glioblastoma is the production and secretion 
of vascular endothelial growth factor A (VEGF-A) (Karcher et al., 2006). When secreted, 
the growth factor binds VEGF receptors located on surrounding epithelial cells which 
induces angiogenesis. The integration of blood vessels in to the tumour provides the 
cancer with its own blood supply, allowing the uptake of nutrients and a way of 
metastasising to other areas of the body.  
1.1.3.2 Oncogenes and Tumour Suppressor Genes (TSGs) 
Whilst RTK signalling may signal to proliferate, downstream mediators may become 
active to deminish the proliferative signal or to stop it all together. Therefore 
mutations must occur in downstream mediators to allow the signal to fully instigate 
proliferation. During RTK signalling, phosphatidylinositol (3,4,5)-trisphosphate (PIP3) is 
phosphorylated which propagates the proliferative activity of PI3K and Akt. PIP3 is 
normally regulated by the phosphatase activity of PTEN, however loss of function 
mutations within this tumour suppressor gene will leave the proliferative activity 
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unchecked and the cell liable to become cancerous (Dahia, 2000). Not only are PTEN 
mutations commonly seen in primary GBMs, but complete removal of the PTEN gene is 
also common due to loss of heterogeneity in chromosome 10, at the P arm (LOH 10p).  
TP53 point mutations are present in 70% of secondary glioblastomas and 30% of 
primary glioblastomas. Loss of heterozygosity (LOH) mutations prevents TP53 from 
carrying out functions which include DNA repair and apoptosis. Mutations can be 
found throughout this pathway and are not just confined to the TP53 protein. 
Amplification of MDM2 and LOH mutations in p14ARF further dysregulate the TP53 DNA 
repair pathway. Mdm2 is involved in TP53 ubiquitination and subsequent degradation. 
Higher levels of the protein due to gene amplification will see intracellular levels of 
TP53 diminish. Mdm2 is subject to regulation by p14ARF, however LOH mutations and 
point mutations make p14ARF redundant and consequently leave Mdm2 to bind and 
degrade TP53. 
A novel aberration that has recently been implicated in glioblastoma is the over-
expression of phosphodiesterase 1C (PDE1C). Although little work has been produced 
on glioma, PDE1C has been implicated in other cancers, such as malignant melanoma 
and osteosarcoma (Ahlstrom et al., 2005, Shimizu et al., 2009). PDE1C hydrolyses the 
second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP). The subsequent modification of these cyclic nucleotides has 
been implicated in cell proliferation in other cell types (Rybalkin et al., 2002). In 
relation to glioma, over-expression of PDE1C was first observed in the immortalised 
human glioblastoma cell lines SNB75 and SF295 (Vatter et al., 2005). Whilst over-
expressed PDE1C was detected, this did not produce any increases in cyclic nucleotide 
hydrolisation, therefore the authors concluded that PDE1C may not be an appropriate 
target for therapeutics. These results may have been caused by the glioblastoma cells 
being immortalised, resulting in genotypic changes and loss of functionality. In 
contrast, previously published data showed a 40% decrease in proliferation when short 
term cultures were treated with PDE1C siRNA and therefore, PDE1C may confer a 
potential therapeutic target (Rowther et al., 2012). Additionally, a study using 
glioblastoma stem cell lines and data from the cancer genome atlas (TCGA) also 
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showed higher PDE1C expression  correlated with shorter survival following surgery 
(Engstrom et al., 2012). 
1.1.4 Prognostic factors 
Various factors impact whether a patient with glioma will successfully enter remission 
or relapse. Age, tumour grade and locale, treatment regime and the presence of 
certain molecular characteristics are all prognostically relevant. When taken in to 
account, these factors can be used to predict the outcome and probability of survival. 
The chances of the patient surviving decreases as the grade of the tumour increases, 
because high grade tumours infiltrate surrounding tissue extensively making complete 
surgical resection difficult, acquire more mutations than lower grade glioma selective 
for cell survival and are more likely to develop resistance to treatment. For instance, 
patients with grade II diffuse astrocytomas have a 50% chance of surviving 5 years 
where as patients with grade IV glioblastoma have a 5% chance of surviving the same 
length of time (Ostrom et al., 2013). Most survival rates decrease with the age of the 
patient, with the elderly having the worse prognosis (table 1.2) (Schwartzbaum et al., 
2006). This is most likely due to poor tolerance of therapy associated side effects 
compared to younger patients. 
Table 1.2- Two year survival rates of glioma with respect to age of diagnosis and glioma-
type, from 1973-2002. 
 Age of 
diagnosis 
(Years) 
Anaplastic 
astrocytoma 
(Grade III) 
Astrocytoma 
(NOS) 
(Grade I – II) 
Anaplastic 
oligodendroglioma 
(Grade III) 
Oligodendroglioma 
 
(Grade II) 
Glioblastoma 
 
(Grade IV) 
Other 
(NOS) 
<20 59% 81.8% N/A 88.8% 27.9% 53.1% 
20-44 71.4% 76% 76.5% 92.3% 29.8% 68.6% 
45-54 44% 41.3% 62.8% 83.7% 11.6% 38.6% 
55-64 19.4% 20% 51.2% 67.1% 6% 26% 
65-74 6.4% 9.1% 29.5% 50.9% 2.7% 12.7% 
75+ 4.1% 5.8% 4.9% 33.3% 1.4% 6.9% 
 NOS – Not otherwise specified. Adapted from Schwartzbaum, et al. (2006) 
The location of the tumour also has an impact on the survival of the patient. Patients 
with glioma located in the parietal lobe are less likely to survive than those patients 
with glioma located in the frontal, temporal or occipital lobe of the brain (Ostrom et 
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al., 2013). Although the reasons for this are currently unknown, tumours within the 
parietal lobe are twice as likely to be malignant than benign and may represent a 
location where glioblastoma is more likely to occur (Sanai et al., 2012). 
Genetic alterations may also inform the clinician how the malignancy will respond to 
treatment. Promoter methylation of the O6-methylguanine-DNA methyltransferase 
gene (MGMT) is a positive prognostic indicator during chemotherapy and 
radiotherapy. MGMT is responsible for DNA repair, reversing the alkylation of guanine 
at the 06 position. Methylation of the MGMT promoter silences the MGMT gene, 
preventing DNA repair, hence cytotoxicity and apoptosis is instigated in glioma 
patients administered alkylating agents, such as temozolomide (TMZ). Although 
promoter methylation is widely seen in grade II and grade III gliomas, hypermethylated 
5`CpG islands are only observed in grade IV glioblastoma.  
Other prognostic factors include the co-deletion of the p arm of chromosome 1 and q 
arm of chromosome 19 (1p/19q) and IDH1/2 function loss. Brandes et al., studied TMZ 
chemotherapy, and in the presence of LOH 1p/19q, they found patients with grade II 
or III oligodendrogliomas and oligoastrocytomas to survive longer (Brandes et al., 
2006).  This was further corroborated during another study, however both noted that 
the loss of one allele did not confer any survival advantage (Kouwenhoven et al., 
2006). IDH1 and 2 are enzymes important to the process of hydrolysing nicotinamide 
adenine dinucleotide phosphate (NADPH). In combination with glutathione, NADPH is 
used to remove reactive oxygen species (ROS) that can result in cellular toxicity (Rusyn 
et al., 2004). Radiotherapy is much more effective in the presence of IDH 1/2 
mutations (Okita et al., 2012), as the ROS produced by ionising radiation is left to 
damage the cancerous cells and induce apoptosis. The IDH1 R132H mutation occurs 
most frequent, present in 93% of gliomas (Hartmann et al., 2009); glioblastoma 
patients with this mutation survive 12 months longer than those with a functional 
IDH1 wild type gene (Lewandowska et al., 2014). 
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1.1.5 Diagnosis 
Glioma is suspected after a clinical history of seizures, limited vision and/or severe 
headaches that may induce vomiting (Weller, 2011). Diagnosis of a suspected case 
involves the collaboration of multiple disciplines, including radiology to confirm a 
suspected lesion, histology to determine cellularity and morphology and molecular 
analysis to determine the tumour grade.  
Diagnosis begins with an MRI confirmed intracranial mass, which is biopsied and 
analysed histologically. Histological examination using haematoxylin and eosin (H&E) is 
routinely performed on all tissue sections; biopsied tissue sections displaying nuclear 
atypia, perinuclear halos and mitotic bodies are indicative of cells that are biologically 
immortal (Weller, 2011). Elucidated morphological characteristics are cross referenced 
with the WHO classification (table 1.1) to determine the tumour subtype. 
Immunohistochemistry (IHC) using antibodies specific to biomarkers present on the 
cell surface may also provide information towards diagnosis (Preusser et al., 2008). 
Qualitative assessment of MGMT, EGFR and IDH1 expression using monoclonal 
antibodies may assist diagnoses. A R132H variation of IDH1 is seen in 93% of 
glioblastoma cases and is therefore an ideal target for IHC (Hartmann et al., 2010). 
Although IHC can be effective inter-observer variability can be an issue, which is most 
likely due to variations in staining intensity. 
 In conjunction with histology, molecular analysis by fluorescence in situ hybridisation 
(FISH) and quantitative polymerase chain reaction (qPCR) may be performed (Masui et 
al., 2012) to quantify genetic aberrations indicative of glioma sub-types, some of which 
were discussed in section 1.1.3. 
1.1.6 Current treatment 
Glioma treatment is tailored individually, as there are many factors that impact how 
the patient will respond. Treatment regimens include surgery, radiotherapy and 
chemotherapy with each modality tailored to tumour size, tumour location, patient 
age and molecular prognostic factors. 
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1.1.6.1 Surgery 
Surgery is performed with the aim of debulking the tumour. Complete resection is 
usually not accomplishable because of the diffuse and invasive nature of glioblastoma. 
In a study of 416 patients who underwent glioblastoma resection, a significant survival 
advantage (median 13 months) was observed where ≥ 98% of the tumour was 
extracted compared to resections under 98% (median 8.8 months) (Lacroix et al., 
2001). 
Brain surgery carries inherent risks as any degree of error can result in detrimental 
effects to autonomic and somatic processes. Although surgery decreases morbidity, 
surgery near areas of the brain responsible for autonomic processes is risky, especially 
when considering the invasiveness of the tumour to the surrounding tissue (Demuth 
and Berens, 2004). Surgery may not even be considered if the tumour has invaded 
certain areas, such as the brain stem or the corpus callosum. Only palliative care may 
be appropriate in these instances; however, targeted therapeutic approaches that are 
able to be delivered systematically may provide better outcomes. 
1.1.6.2 Radiotherapy 
Radiotherapy is the use of ionising radiation to damage DNA. DNA repair mechanisms 
initiate apoptosis when cellular toxicity is reached. Cells undergoing proliferation are 
more sensitive to radiation; causing the cancerous cells to incur irreversible DNA 
damage. The treatment is administered in small fractions (1.8-2 Gy) equating to a 60 
Gy dose. Small doses give the surrounding healthy tissue adequate time to recover 
from any non-specific damage. The overall dose is reduced to 40 Gy when treating 
patients over 70 years old as it is better tolerated (Weller, 2011). Tumours exhibiting 
TP53 (loss of function) mutations are less sensitive to radiotherapy as programmed cell 
death is initiated less frequently (Yount et al., 1996).  
Radiotherapy following surgery has been shown to give patients a better chance of 
survival (Stupp et al., 2005), however radiotherapy may cause adverse reactions, 
including secondary cancers and impaired memory loss amongst others (Newhauser 
and Durante, 2011, Surma-aho et al., 2001). Cancerous cells are liable to 
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radioresistance, prompting glioma stem cells to express CD133 or Prominin-1 as a 
consequence of radiotherapy (Bao et al., 2006). Upon radiation induced DNA damage, 
Prominin-1 will halt proliferation and repair any damage caused (Bao et al., 2006). 
Wang et al., showed that the Notch signalling pathway is needed for glioma 
radioresistance to occur. The pathway is needed for cell maintenance and cell-to-cell 
communication, and upon Notch inhibition, the cells were re-sensitised to radiation. 
The lack of selectivity produces inherent therapy associated side effects; moreover 
radiotherapy may leave residual cells behind that are resistant to ionising radiation. 
1.1.6.3 Chemotherapy 
As part of the National Institute for Health and Care Excellence (NICE) guidelines for 
glioma treatment, chemotherapy such as procarbazine, lomustine, vincristine (PCV), 
temozolomide (TMZ) and carmustine implants are implemented as an adjunct to 
radiotherapy (NICE, 2007). Chemotherapeutic agents, such as temozolomide, alkylate 
guanine nucleotides and upon cellular toxicity, apoptosis occurs (Wen and Kesari, 
2008). Cancerous cells are more sensitive to chemotherapies because of their 
increased proliferative activity. 
Carmustine wafers are biodegradable implants that are placed within the resected 
area of the brain following surgery. By directly placing the wafers within the resected 
cavity, the  blood brain barrier (BBB) is bypassed and carmustine is directly released to 
target residual cancerous cells. Whilst the technology was approved for use in the UK, 
glioblastoma patients treated with carmustine implants did not exhibit a significant 
overall survival advantage when compared to the placebo group (NICE, 2007). Instead, 
a sub-group with 90% of the tumour excised, was identified with an overall survival 
gain of 4.2 months.  
TMZ is an alkylating agent administered cyclically for 42 days with adjuvant 
radiotherapy. Higher doses are administered without radiotherapy for 5 days followed 
by a 23 day break. Six cycles are administered, during the second and subsequent 
cycles TMZ can be given at higher doses upto 200mg/m2 (NICE, 2007). Using the 
treatment regime described, Athanassiou et al., showed patients with glioblastoma 
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survived longer when treated using TMZ combined with radiotherapy (13.4 months), in 
contrast to radiotherapy alone (7.7 months) (Athanassiou et al., 2005). In contrast, 
another study noted that > 60% patients do not gain any benefit from TMZ, although 
20% develop significant toxicity (Chamberlain, 2010).   
During tumour reoccurrence, combinatorial treatment PCV is part of the first line 
treatment. Whilst it is standard practise, the effectiveness of PCV has shown to be 
poor and does not confer any significant survival advantage (NICE, 2001). The same 
conclusion has been corroborated in subsequent studies, which also found 
haemotoxicity commonly occurred in 26% of patients (Kappelle et al., 2001, Schmidt et 
al., 2006). Subsequently, TMZ has been recommended as an alternative to PCV and has 
been shown to have better outcomes, with respective progression-free survival rates 
of 21% compared to 8% respectively (NICE, 2001). 
All of the aforementioned drugs may cause unwanted side effects and could 
potentially make recurrent tumours more difficult to treat. Chemotherapeutics cause 
collateral damage as labile cells are more sensitive to these drugs. Rapidly dividing cells 
such as white and red blood cells, hair cells and skin cells are particularly susceptible to 
toxicity (Weller, 2011). Chemotherapeutic drugs have also been associated with 
multidrug-resistant proteins (MRPs) being over-expressed and TMZ therapy can result 
in MGMT promoter activation (Salmaggi et al., 2006, Sarkaria et al., 2008). Higher 
expression of MRPs have been found to occur in glioblastoma stem cells as a 
consequence of chemotherapy making reoccurring tumours harder to treat (Salmaggi 
et al., 2006). TMZ may cause the MGMT promoter to be demethylated, resulting in 
increased production of the MGMT DNA repair protein. MGMT will remove alkyl 
groups from guanine nucleotides in response to TMZ and is thought to be a major 
protein involved in chemoresistance (Sarkaria et al., 2008). Aptamers have been 
proposed as a targeting system that could deliver chemotherapeutic drugs specifically 
to cancerous cells, which would help reduce unwanted systemic side effects as well as 
reducing resistance if higher concentrations of drug could be delivered to the site of 
action. 
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1.2 Aptamers 
1.2.1 History of Aptamers 
During the 1980’s, studies into the replication of HIV-1 and adenoviruses revealed 
short regulatory RNA sequences that interacted with specific proteins. For example, a 
59 base sequence known as the trans-activation responsive (TAR) element precedes 
HIV-1 genes. TAR produces a tertiary structure that specifically interacts with the trans-
activator (Tat) of HIV; a protein required for efficient transcription of HIV-1 genes and 
consequently, HIV-1 replication (Dollins et al., 2008). These studies revealed that short 
sequences of nucleic acids could interact with and affect the function of proteins.  
In 1990, the first organic aptamers were independently produced by two different 
groups, Ellington and Szostak, and Turk and Gold. Ellington and Szostak coined and 
defined the term aptamer, a short sequence of RNA or single-stranded DNA (ssDNA) 
selective to a target molecule (Ellington and Szostak, 1990). Ellington and Szostak 
selected RNA aptamers from a pool of 1013 unique sequences towards two chemically 
similar dyes. Although the dyes were similar in structure, they found that the 
sequences were specific towards the dye they were selected for and did not cross 
react. It was therefore demonstrated that aptamers were able to differentiate 
between similar targets.  During Tuerk and Gold’s study, RNA aptamers were selected 
from a pool of 65,000 unique sequences derived from a wild-type sequence already 
known to interact with the target. It was noted that selected sequences were 
structurally similar to the wild-type and the synthetic aptamers disassociation constant 
(Kd) was similar to the wild-type. As well as showing aptamers selected synthetically 
were just as good as those selected by nature, Tuerk and Gold pioneered the simple 
methodology which can be applied to select specific aptamers to a target. They coined 
this process Systematic Evolution of Ligands by Exponential Enrichment (SELEX) (Tuerk 
and Gold, 1990).  
1.2.2 Structure and function 
Aptamers have the ability to distinguish between proteins that are 96% similar and this 
allows for aptamers to be selected towards analogous proteins with high selectivity 
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and affinity. This trait is a consequence of the tertiary structure that the short 
nucleotide sequence conforms to (Fig 1.3). Secondary structures are defined by either 
Hoogsteen base pairing or Watson-Crick base pairing. Figure 1.3A shows the secondary 
structure of an RNA aptamer abiding by Watson-Crick complementation, where 
adenine pairs uracil (or thymine in DNA) and cytosine pairs guanine. Figure 1.3B shows 
the secondary and tertiary structure of a DNA thrombin binding aptamer (TBA), the 
secondary structure produced is a result of Hoogsteen complementation. Hoogsteen 
base pairing is the hydrogen bonding at the N7 position of the purines; this is in 
contrast to the N3 or N4 position which occurs in Watson-Crick base pairing. The 
change in position means that very stable guanine-quadruplexes are able to form in 
sequences that are guanine-thymine rich. 
 
Figure 1.3 – The primary, secondary and tertiary structure of RNA and DNA aptamers. A: The 
primary and secondary structure of a 95mer RNA aptamer selected against Reactive Blue 4 
dye. The secondary structure is created through Watson-Crick base pairing, primer regions are 
shown in red (Ellington and Szostak, 1990). B: The secondary and tertiary structure of a 15mer 
DNA aptamer selected against α-thrombin. The secondary structure is produced by Hoogsteen 
base pairing which subsequently fosters guanine-quadruplexes. The tertiary structure shows 
how the aptamer (red) interacts with the α-thrombin (grey). Figure adapted from Pasternak et 
al, (2011).  
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The tertiary structure of the aptamer is based on weak electrostatic interactions such 
as hydrogen bonding, Van der Waals forces and base stacking between adjacent 
aromatic residues (Mayer, 2009). Whilst many nucleotides will pair in any given 
aptamer sequence, those that are left unpaired produce stem loops containing 
potential binding sites (Duconge and Toulme, 1999). Hydrogen bonding and Van der 
Waal interactions are necessary for the aptamer binding to the target, which can only 
occur when stem loops containing unpaired nucleotides are present (Mayer, 2009). 
Protein targets with enzymatic functions bind substrates through weak electrostatic 
interactions. Consequently aptamers interact with the enzymatic active site through 
the same interactions in which the substrate would, blocking the substrate from 
binding, and hence are capable of inhibiting activity (Lin and Jayasena, 1997, Ikebukuro 
et al., 2007, Townshend et al., 2010, Simmons et al., 2014). 
The identification of specific DNA aptamers has been favoured over RNA aptamers, as 
they are more stable and cost-effective. As well as thymine being replaced by uracil, 
RNA has a 2’ hydroxyl group as opposed to the 2’ hydrogen molecule present in DNA. 
Consequently, the phosphoester bond between the ribose sugar and phosphate group 
may be degraded and cleaved internally. Despite being less stable, RNA aptamers are 
reported to produce more diverse and versatile shapes, although some RNA aptamers 
have been converted in to the DNA counterpart and still retained functionality (Mok 
and Li, 2008). 
1.2.3 Aptamers versus antibodies  
Cancer therapies, such as those discussed in Section 1.1.6, lack specificity and could 
potentially leave residual cancerous cells behind which could proliferate and become 
harder to treat. Chemotherapies conjugated to a targeting ligand, such as aptamers 
and antibodies, offer attractive solutions and could be exploited to produce a more 
targeted approach to therapy. There are many antibody alternatives including 
anticalins (Schlehuber and Skerra, 2005) and adhirons (Tiede et al., 2014). Aptamers 
are widely acknowledged to be ‘chemical antibodies’, comparisons between the two 
targeting ligands have shown that they exhibit similar levels of affinity and selectivity 
to the chosen targets. 
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Monoclonal antibodies within cancer immunotherapy has been in use over the last 30 
years and although an attractive solution, some challenges are still yet to be overcome. 
A challenge antibodies find difficult to overcome is bypassing the blood brain barrier. 
Antibodies are large multimeric proteins that are heavily glycosylated in order to retain 
stability, as a consequence of this the large molecular weight and the presence of 
efflux transporters within the BBB, such as P-glycoprotein, may prevent antibodies 
from crossing (Banks, 2009). An attractive candidate for cancer immunotherapy has 
been the cancer specific EGFRvIII mutation, present in 75% of glioblastoma exhibiting 
EGFR amplification. Using a murine model, a monoclonal antibody was isolated that 
specifically targeted EGFRvIII (Sampson et al., 2000). The group noted that systematic 
treatment produced no overall survival advantage, whilst a significant increase was 
observed when the antibody was directly applied intracranially.  
Antibodies are produced in vivo through an animal host, which are subsequently 
humanised or changed in to a chimeric antibody by substituting the Fc region. Whilst 
they are changed to prevent the administered antibody from potentiating an immune 
response, there is still a chance the immune system will recognise the antibody as 
foreign and could produce a life threatening allergic response. Whilst isolated anti-
EGFRvIII monoclonal antibodies have thus far been made redundant, the targeting of 
the wild type EGFR has been moderately successful. Cetuximab, a chimeric anti-EGFR 
antibody, was shown to be potentially effective in treating glioblastoma when 
combined with chemotherapy and radiotherapy using mice models (Eller et al., 2005). 
The effectiveness of cetuximab was trialled in humans more recently and a number of 
adverse events were recorded including grade 3 allergic responses to the skin, for 
which one patient needed plastic surgery (Hasselbalch et al., 2010). In contrast to 
antibodies, aptamers are stable ligands that have been shown to cross the BBB and are 
not immunogenic (Cheng et al., 2013, Foy et al., 2007).  
In comparison to antibodies, aptamers are relatively small and are able to penetrate 
the cell once bound to the target present on the cell surface, which would improve 
delivery of chemotherapeutic payloads. Whilst antibodies are the more commercially 
established targeting ligand, aptamers are identified through the in vitro process of 
SELEX and do not need the use of animals. As specific aptamers are isolated in vitro, 
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the process can be controlled and changed to suit the application for which it is meant 
for. Aptamers, unlike antibodies, are able to be counter selected against a compound 
that is analogous to the target (Sefah et al., 2010b). This reduces the chances of the 
aptamer cross reacting and increases specificity to the target of choice. 
NICE guidelines have reviewed an RNA aptamer, pegaptanib (branded Macugen, by 
Pfizer), and a monoclonal antibody, ranibizumab (branded Lucentis), for the treatment 
of neovascular or wet age-related macular degeneration (AMD) (Harding, 2008). 
Neovascular AMD arises due to abnormal angiogenesis, resulting in a build-up of 
exudates within the eye (Ishida et al., 2003). NICE concluded that whilst both 
treatments were well tolerated, ranibizumab was more effective. Whilst ranibizumab 
is recommended as first line treatment, it should be noted that pegaptanib is cheaper 
and specifically targets the angiogenic VEGF-165, whereas the monoclonal antibody 
targeted all isoforms of VEGFα (Harding, 2008). 
1.2.4 Identification of aptamers by SELEX 
First described by Tuerk and Gold, SELEX is the basic process used to identify functional 
aptamers to an employed target (Tuerk and Gold, 1990). During SELEX, a starting pool 
of 1015 unique oligonucleotides is amplified and incubated with a counter selection, 
which is analogous to the target. Unbound sequences are then exposed to the target 
of choice (Jenison et al., 1994). Aptamers bound to the target are eluted and amplified 
via polymerase chain reaction (PCR), utilising constant regions flanking either side of 
the randomised sequence. The amplified aptamers are then purified and concentrated 
in-order to control the reaction volume for the following round of selection. A 
summary of SELEX can be seen in Figure 1.4. 
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Figure 1.4  – Systematic Evolution of Ligands by Exponential Enrichment (SELEX).  A nucleic 
library is incubated and filtered using a negative control and a positive selection. The aptamers 
eluted from the positive selection are amplified, concentrated and are used for further rounds 
of SELEX selection until a minority emerge. Figure adapted from Sefah, et al. (2010). 
SELEX is produced in iterative cycles to evolve the starting naive library in to a pool of 
aptamers selective for the desired target. As rounds are produced, the competition for 
the epitope increases, however conditions can be made more stringent which impacts 
the aptamer affinity and Kd for the target. Over the last 20 years, the original SELEX 
process has been modified and updated to produce more than 25 different variations 
of the method (Aquino-Jarquin and Toscano-Garibay, 2011). Whilst the basic 
foundations of selection, elution, amplification and purification have stayed consistent, 
updated and less laborious technologies have been introduced producing aptamers of 
higher quality with better functionality. Some of the major advances are described in 
Table 1.3. 
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Table 1.3 – SELEX modifications to select aptamers more effectively or of higher quality
 SELEX name Modification References 
Capillary 
electrophoresis 
SELEX (CE-SELEX) 
Capillary electrophoresis can be used to 
separated free and complexed molecules 
based on electrophoretic migration. CE 
incorporation leads to a high rate of 
enrichment which subsequently lowers the 
number of SELEX rounds needed to select 
aptamers with high affinity. 
(Mendonsa and 
Bowser, 2004) 
Spielgamer SELEX DNA and RNA aptamers have short half-lives in 
vivo. Whilst the aptamers may be chemically 
altered to increase the half-life, spielgamer 
technology selects aptamers using a 
dextrorotatory aptamer library. The 
corresponding levorotatory sequence can be 
then used to prevent nuclease degredation; 
however this requires the target to have 
optical activity. 
(Klussmann et 
al., 1996) 
FluMAG SELEX FluMAG utilises a target immobilised to a 
magnetic bead in which fluorescently labelled 
aptamers are targeted to. Magnetic beads 
allow complexed aptamers to be separated 
efficiently, which are amplified using a 
fluorescently labelled primer.  
(Stoltenburg et 
al., 2005) 
 
1.2.5 Review of aptamer applications 
The SELEX process has been adapted to fit a wide range of targets, ranging from 
peptides to proteins and from viruses to whole cells, and hence a wide range of 
aptamer applications have been produced some of which, are described in the 
following sections. 
1.2.5.1  Aptamers as therapeutic agents 
The first Food and Drug Administration (FDA) approved aptamer was pegaptanib, for 
the treatment of neovascular age-related macular degeneration. Subsequently, Jellinek 
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et al. (1994) produced RNA aptamers that were 28 nucleotides long and specific to 
VEGF-165. The group showed that the aptamer blocked the angiogenic growth factor 
from interacting with the VEGF receptor in a dose-dependent manner, which exhibited 
a Kd in the 10-20 nM range. 
VEGF-165 specific aptamers were modified and enhanced by Ruckman et al. (1998) by 
truncating to the minimal binding site consisting of 7 nucleotides. As these small 
ligands would have been liable to renal filtration if administered without any 
modifications, a 40kDa PEG moiety was added. The 7 nucleotides within the RNA 
aptamer were all modified with a 2’-O-methyl group to prevent internal degradation 
and external degradation via RNAses. The authors noted that the modified versions 
retained their affinity for the target VEGF-165, even though it was slightly reduced. 
One sequence out of the three modified, called  pegaptanib, showed that it was a 
potent inhibitor of VEGF-induced vascular permeability (Ruckman et al., 1998). 
An anti-cancer aptamer called AS1411 has shown to be a promising therapeutic 
candidate for multiple cancer types, such as metastatic renal cell carcinoma 
(Rosenberg et al., 2014), breast cancer (Soundararajan et al., 2008) and glioma (Guo et 
al., 2011). AS1411 is a DNA aptamer 26 nucleotides in length that targets nucleolin, a 
protein found on the surface of proliferating cells and is overexpressed on the surface 
of cancerous cells. Although the mechanism of action is not clear, it is proposed that 
the complex is internalised and destabilises mRNA encoded to produce B-cell 
lymphoma protein 2 (BCL-2); an anti-apoptotic protein (Chen, et al., 2008). AS1411 
does not bind or affect nucleolin found on normal, healthy cells (Soundararajan et al., 
2009). During a recent phase II clinical trial, where 35 patients with metastatic renal 
cell carcinoma was enrolled, only one patient had a good response with the tumour 
shrinking by 84%. AS1411 was considered to be tolerated well, with one third of 
patients showing moderate adverse effects (Rosenberg et al., 2014). 
1.2.5.2 Aptamers for target identification 
Aptamers are able to interact with certain biomarkers; however they may not have any 
therapeutic benefit once internalised. The in vitro identification of specific aptamers 
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means that they may be modified with various conjugates to add medicinal 
functionality (Ireson and Kelland, 2006). Therapeutic agents, such as chemotherapeutic 
drugs, interfering RNA and toxins, have been paired with aptamers, producing a 
targeted approach to therapy whilst sparing healthy tissue. One well studied aptamer 
in the delivery of functional conjugates is the prostate specific membrane antigen 
(PSMA) aptamer, A10 (Lupold et al., 2002). The 40 nucleotide long RNA aptamer is 
internalised once complexed with its target and does not have any therapeutic effect. 
Prostate cancer therapy has been investigated using A10 conjugated to siRNA (Dassie 
et al., 2009), toxins (Chu et al., 2006), chemotherapeutic drugs (Bagalkot et al., 2006) 
and nanoparticles (Dhar et al., 2008). 
Small interfering RNA (siRNA) hybridises messenger RNA (mRNA) normally translated 
to protein pivotal for cellular processes. Upon hybridisation, the mRNA is degraded 
and cytoplasmic levels of the protein for which it encoded is decreases. siRNA is an 
attractive treatment modality, however treatment efficacy is usually mitigated by poor 
selectivity. A10 conjugated to siRNA has shown to be effective in reducing Bcl-2 levels 
(Dassie et al., 2009), which is over-expressed in prostate cancer and has anti-apoptotic 
effects. 
Chemotherapeutic agents, such as cisplatin, have been encapsulated in nanoparticules 
in-order to improve targeted drug therapy (Dhar et al., 2008). Cisplatin associated side 
effects, such as anaemia and nephrotoxicity may be mitigated utilising such aptamer 
bound vehicles. Liposomes, utilising aptamers modified with cholesterol, has also been 
implicated to improve drug delivery.    
1.2.6 Use of aptamers in the targeting of glioma 
Throughout the previous sections, the issues surrounding current treatment modalities 
for glioma have been reviewed whilst the versatility of aptamers as a targeting ligand 
have been outlined. Previous studies have produced aptamers that are specific to 
glioma. Cerchia et al., and Kang et al., selected aptamers towards the glioblastoma 
cells lines U87MG and U251 (Cerchia et al., 2009, Kang et al., 2012), using modified 
cell-SELEX procedures (Fitzwater and Polisky, 1996, Sefah et al., 2010b).  
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Identified aptamers showed affinities towards the glioblastoma cells line, with minimal 
affinity to the negative selections used. The aptamers, GBM128 and GBM131, selected 
by kang et al., also showed affinities for other glioma tissues, including anaplastic 
oligodendroglioma and pilocytic astrocytoma, implicating a common target (Kang et 
al., 2012). Both groups showed that aptamers could be identified that are disease 
specific, which could be further utilised for medicinal applications. 
1.3 Aims and objectives of study 
The aim of this study was to identify novel DNA aptamers using cells from short term 
glioblastoma cultures. Whilst the slow growth of short term cultures may limit 
aptamer identification, a cell-SELEX protocol using minimal cell numbers was 
investigated in order to circumvent issues with slow growth. Furthermore, purified 
proteins that are known aberrations previously shown to be of importance in 
gliomagenesis, such as EGFRvIII and PDE1C were used for aptamer identification. 
Isolated aptamers were validated to determine whether the aptamers interacted with 
the protein target. 
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Chapter 2: Methods and materials 
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2.1 Cell culture and maintenance. 
2.1.1 Cell lines and primary cell cultures 
The cell lines SVGp12 and U87MG were used to optimise the cell-SELEX procedure. 
SVGp12 is a human foetal astroglia cell line that was used as the negative selection 
within SELEX selections and was obtained from the American Type Culture 
Collection (ATCC). U87MG is a human astroglia cell line representative of grade IV 
glioblastoma multiforme and was used as the positive selection within SELEX. 
U87MG was obtained from the European Collection of Cell Cultures (ECACC). 
2.1.2 Cell Culture and Subculture 
SVGp12 and U87MG were cultured in Eagles minimal essential medium (EMEM, 
Bio-Whittaker) supplemented with 10% foetal bovine serum (FBS, Bio-Sera), 1% 
non-essential amino acids (NEAA, Sigma UK), 2 mM L-Glutamine and 1 mM Sodium 
pyruvate (Sigma UK). Cell cultures were incubated at 37°C in a humidified 5% CO2 
environment and were subcultured to 80% confluency.  
Once cell cultures reached confluency, the media was removed and cells were 
washed with phosphate buffered saline (PBS, pH 7.4) to remove residual media. 
Cells were removed from the flask through incubation at 37°C in 2ml of 1 x trypsin 
diluted in PBS, for 2 minutes. To inhibit the trypsin, EMEM was added at an equal 
volume and the cell suspension was centrifuged for 5 minutes at 200 x g. The 
supernatant was removed and the cell pellet was resuspended in fresh media. 
Appropriate dilutions were added to 10ml of EMEM (1:3 for SVGp12, 1:6 for 
U87MG) and incubated until required. 
2.2.3 Cell Viability 
Non-viable cells can bind aptamers non-selectively resulting in the loss of aptamers. 
The trypan blue exclusion assay was performed on cell cultures to determine cell 
viability. After trypsinisation, a homogenous cell suspension was aliquoted and 
trypan blue (Sigma UK) was added at a ratio of 1:1. The cells were checked for the 
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presence of non-viable blue cells and cell suspensions with ≥95% viability (non-
viable/total cell count x 100) were used in SELEX selections. 
2.3 Optimisation and establishment of an aptamer library. 
2.3.1 The DNA aptamer library 
Specific aptamers were selected from a large library of random oligonucleotides. In-
order to create the library, 1015 potentially unique DNA aptamers were synthesised 
by Integrated DNA Technologies (IDT, UK) through machine mixed randomisation. 
All dNTPs were included at different ratios to avoid asymmetric binding efficiency 
and either side of the sequences were flanked by conserved regions. The aptamer 
template was as follows: 
5`-ATCCTAATACGACTCACTATAGGGAGAGAATTC – N50 – 
GAATTCTGCGGTAAACTCGAGGG-3` 
The random region of 50 nucleotides (green) was flanked by a forward primer (red) 
and a reverse primer (blue), which was conserved throughout all sequences and 
were required for amplification by PCR. 
2.3.2 Amplification of the DNA aptamer library 
Inefficient amplification of DNA aptamers may result in the production of non-
specific sequences, these sequences may compete with the specific sequence 
during SELEX selections, therefore reducing the efficiency of aptamers 
identification. In-order to reduce non-specific amplification, touchdown polymerase 
chain reaction (TD-PCR) was trialled as previously described by Korbie and Mattick 
(2008) and was validated in comparison with standard PCR. To compare the 
programmes, the optimal number of cycles for each programme was investigated. 
The annealing temperature of the forward and reverse primers (IDT, UK) was 
optimised previous to this study and was found to be optimal at 50°C (Table 2.1). 
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Table 2.1 – Primer sequences and properties 
Primer Name Sequence of primer Melting 
temperature (Tm) 
GC 
Content 
AptForward 5`-ATCCTAATACGACTCACTAT-3` 46°C 35% 
AptReverse 5`-CCCTCGAGTTTACCGCAGAATT-
3` 
57°C 50% 
 
PCR reactions (Table 2.2) were amplified through TD-PCR and standard PCR 
programmes (Table 2.3). Control reactions were conducted in the absence of Taq 
polymerase. PCR products were aliquoted at increments of 5 cycles and were 
separated and visualised by agarose gel electrophoresis (see Section 2.2.3).  
Table 2.2 – Reagents used for amplification of DNA aptamer library 
Reagent Final Concentration 
5x PCR buffer 1x 
Deoxynucleotide Solution 200µM 
AptForward 0.5µM 
AptReverse 0.5µM 
Template DNA (Aptamer library) 10µg/µl 
MgCl2 1 mM 
DNA Taq polymerase 0.02 U/ul 
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Table 2.3 – Touchdown and Standard PCR programmes used for the amplification of the 
DNA aptamer library. 
Action Time 
(Seconds) 
Temperature (°C) 
TD-PCR 
Temperature (°C) 
Standard PCR 
Initial 
Denaturation 
300 95 95 
Phase One (10 Cycles) 
Denaturation 30 95 - 
Annealing 30 60 (decreased 
1°C/cycle) 
- 
Extension 30 72 - 
Phase Two (30 Cycles) 
Denaturation 30 95 95 
Annealing 30 50 50 
Extension 30 72 72 
 
Final Extension 420 72 72 
 
2.3.3 Separation and visualisation of PCR products 
Amplified PCR products were separated and visualised via agarose gel 
electrophoresis. PCR products were mixed with bromophenol blue (0.25% w/v 
bromophenol blue, 0.25% w/v xylene cyanol and 30% glycerol) at a ratio of 1:1 and 
separated on a 2% agarose gel (Fisher scientific, UK) prepared with 1 x TAE buffer 
(1.85 M Tris, 45 mM EDTA and 1M Glacial Acetic acid), containing 0.005% of 
SafeView nucleic acid stain (NBS Biologicals). After separation, the amplified PCR 
products were visualised under UV light. 
2.3.4 Purification of DNA via ethanol precipitation 
Dilute PCR products will lower stringency, decreasing the efficacy of SELEX 
selections, therefore the DNA aptamers were concentrated in-order to control the 
stringency of SELEX selections. A modified DNA precipitation procedure utilising the 
DNA carrier glycogen, as described by Fregal et al., was compared with the standard 
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ethanol precipitation protocol. Furthermore, the temperature and concentration of 
glycogen used to facilitate precipitation was optimised. 
A loading control was aliquoted from pooled PCR product (section 2.2.2) and the 
remaining DNA aptamers were distributed evenly between 6 precipitations (Table 
4). For the standard procedure, 1/10th volume of sodium acetate (3M) and 2 
volumes of cold 100% ethanol (-20°C) was added to the PCR product. The mixture 
was incubated at the appropriate temperature for the allotted time, which was 
then centrifuged at 14,100 x g for 15 minutes at 4°C. The supernatant was 
discarded and the pellet was washed in cold 70% ethanol (-20°C) and centrifuged 
again. The supernatant was removed and the pellet was air dried for 5 minutes 
before being resuspended in dH2O.  
For the modified protocol, stock solutions of glycogen were prepared (50 mg/ml 
and 100 mg/ml) in 75 mM ammonium acetate. To the PCR product, 1/10th volume 
of ammonium acetate (75 mM) with glycogen was added, as well as 2 volumes 
100% cold ethanol (-20°C). The mixture was incubated at the appropriate 
temperature for the allotted time and before centrifugation. The supernatant was 
removed and the pellet was air dried for 5 minutes at room temperature before 
being resuspended in dH2O. 
Table 2.4 – The different precipitation protocols and varied temperatures and glycogen 
concentrations used to optimise DNA precipitation 
Incubation at -80°C for 1 hour Incubation at -20°C for 24 hour 
Standard protocol Standard protocol 
Modified with Glycogen (5mg/ml) Modified with Glycogen (5mg/ml) 
Modified with Glycogen (10 mg/ml) Modified with Glycogen (10mg/ml) 
 
2.3.5 Preparation of ssDNA aptamers from concentrated PCR product 
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Following resuspension in an appropriate volume of dH2O, amplified DNA aptamers 
were prepared as previously described by Sefah et al.,(2010). Binding buffer (25 
mM glucose, 0.1% bovine serum albumin, 0.25 mM MgCl2 and 1 x PBS) was added 
to the DNA aptamers and heated to 95°C for 5 minutes. Following denaturation, the 
ssDNA was snap-cooled on ice for 5 minutes and kept on ice or stored at 4°C until 
required. 
2.4 Systematic evolution of ligands by exponential enrichment using cell 
lines (cell-SELEX). 
2.4.1 Negative Selections of amplified library against SVGp12 cell line 
To ensure selected aptamers were specific to the positive selection, snap-cooled 
ssDNA aptamers were exposed to a negative selection of the non-cancerous 
SVGp12 astrocyte cell line. Subcultured SVGp12 were trypsinised (section 2.1.3) and 
viability was assessed (Section 2.1.4). Cells were washed with washing buffer 
(25mM glucose, 0.25mM MgCl2 and 1X PBS) and centrifuged at 200 x g for 5 
minutes to remove excess media. Cells were resuspended in binding buffer and the 
ssDNA aptamers were added (total volume 700µl). SVGp12 cells were then 
incubated at 4°C for 1 hour with shaking. After incubation the cells were 
centrifuged at 200 x g for 5 minutes and the supernatant was retained for use in the 
positive selection. 
2.4.2 Positive selections against U87MG cell line 
Aptamers which did not bind to the negative selection were carried forward in to a 
positive selection against U87MG. Cells were prepared as described previously 
(section 2.4.1) and the aptamers retained from the negative selection was added to 
the U87MG cells. The mixture was incubated at 4°C for 1 hour with shaking. After 
incubation the cells were centrifuged and the cells were washed with washing 
buffer three times to remove any unbound aptamers. Cells were resuspended in 
dH2O and heated to 95°C for 10 minutes to elute any bound aptamers. The cells 
were centrifuged at 14,100 x g for 1 minute and the supernatant was retained. 
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Eluted aptamers were then amplified via PCR (section 2.2.2), concentrated by 
ethanol precipitation (section 2.2.4), quantified by gel electrophoresis (section 
2.2.3), snap-cooled on ice (section 2.2.5) and reapplied in to iterative rounds of 
SELEX. 
2.4.3 Minimum number of cells required to return specific aptamers 
In-order to establish the minimum number of cells which would return selective 
aptamers, a round of SELEX was performed using SVGp12 (section 2.3.1) and 
U87MG (section 2.3.2). The aptamer library was applied to cell numbers of 
1000x103, 500x103, 250x103, 125x103, 62.5x103, 32x103, 16x103, 8x103, 4x103, 
2x103, 1x103, 0.5x103, 0.25x103 and 0.1x103. Cell numbers were constant through 
negative and positive selections.  
The minimal cell number that returned sufficient bound aptamers was put through 
5 rounds of SELEX to confirm the cell number could be used for the identification of 
aptamers. After each round of selection, the number of PCR programme cycles was 
optimised to determine the number of cycles that returned the optimal yield of 
aptamers, but with maximum specificity. This was performed as in section 2.2.2 and 
amplified DNA aptamers were concentrated by the optimised ethanol precipitation 
procedure and visualised by agarose gel electrophoresis. 
2.5 Primary cell SELEX 
Two glioblastoma short-term cell cultures, BTNW390 and BTNW914, were obtained 
from the Brain Tumour North West tissue bank located at Royal Preston hospital, 
UK. BNTW390 primary cells were extracted from an 80 year old male and BTNW914 
primary cells were biopsied from a 64 year old female. Normal human astrocytes 
(NHA) were cultured in AGM Astrocyte Growth Bulletkit (Lonza). Short-term patient 
samples were cultured in F10 HAM (Sigma, UK) supplemented with 10% FBS of 
(LifeTechnologies, Australia). Cultures were incubated at 37˚C in a humidified CO2 
environment. 
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To harvest cultured NHA cells, the cells were washed with dulbeccos phosphate 
buffered saline (DPBS). Following washes, the cells were removed by incubating at 
37˚C in trypsin EDTA for 2 minutes. Astrocyte media was added at equal amounts to 
inhibit the trypsin and cells were centrifuged 200 x g, and washed three times to 
remove residual media and trypsin before being entered in to SELEX selections. 
Short-term cell cultures were washed with PBS and subsequently harvested by 
incubating for 4 minutes at 37˚C in 2x trypsin. F10 HAM was added at an equal 
concentration to inhibit the trypsin, before being centrifuged at 200 x g. Cells were 
washed three times before being entered in to SELEX selections. 
Five rounds of SELEX from the short-term cultures were produced. ssDNA aptamer 
libraries (prepared as in Section 2.3.5) were incubated with NHA cells for 60 
minutes at 4˚C on a rocker shaker. Following incubation, cells were pelleted by 
centrifugation at 200 x g and the supernatant, containing unbound aptamers, 
underwent positive selection. Unbound aptamers were incubated with the short 
term cultures for 60 minutes at 4˚C with shaking. Following incubation, the cells 
were pelleted by centrifugation at 200 x g and the cells were washed with washing 
buffer three times, before the aptamers were eluted in dH2O by heating to 95˚C for 
5 minutes. The cell-SELEX selections for both short term cultures were produced 
separately and after five rounds of selection, aptamers still present were cloned 
and sequenced. 
2.6 Identification of DNA aptamers towards purified biomarkers via 
Counter-SELEX 
2.6.1 Counter-SELEX against Phosphodiesterase 1C (PDE1C) 
To produce aptamers specific to PDE1C, one negative selection against glutathione 
S-transferase (GST) and one negative selection against agarose resin were 
performed. The resulting pool of filtered aptamers were positively selected against 
GST tagged PDE1C during 6 rounds of positive selection. 
2.6.1.1 Expression of glutathione S-transferase (GST) 
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pGEX-KG vector (fig 2.1) was added to chemically competent BL21 E.coli cells 
(genotype: BF–dcm ompT hsdS(rB–mB–)gal) and incubated on ice for 30 minutes. 
Cells were heat shocked at 42˚C for 90 seconds before being snap cooled on ice for 
2 minutes. Transformed cells were spread on to pre-warmed LB agar plates 
containing 25µg/µl ampicillin and were incubated overnight at 37˚C. Control plates 
were produced by substituting pGEX-KG vector with dH2O. 
Transformed BL21 E.coli cells were inoculated in to LB broth and incubated at 37 ˚C 
with shaking. The optical density (abs 600nm) of the culture was monitored. When 
the culture reached an OD600nm of 0.6, 1mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) was added to the culture to induce GST expression. The induced culture was 
left for 210 minutes at 37 ˚C with shaking at 180rpm. 
Cells were harvested via centrifugation at 16,000 x g for 10 minutes at 4 ˚C, the 
supernatant was discarded and the cells were washed with dH2O. Following 
centrifugation and removal of the supernatant, cells were resuspended in 1x PBS 
before sonication. BL21 cells expressing GST were lysed by intermittent cycles of 
sonication of 30 seconds, at an amplitude of 14. Cellular fragments were pelleted 
by centrifugation at 16,000 x g and the supernatant, containing soluble intracellular 
proteins, was retained. 
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Figure 2.1 – Map of the pGEX-KG vector transformed in to chemically competent BL21 
E.coli for the expression of GST. 
  
SDS-PAGE gel electrophoresis was performed to confirm successful expression of 
GST. BL21 E. coli before and after induction of GST expression were heated to 95˚C 
for 5 minutes in 1x Laemelli buffer (65mM Tris-HCl pH 6.8, 10% glycerol, 1% SDS, 
0.0025% bromophenol blue). Samples were loaded on to a 4-20% gradient mini-
protean gel (BioRad, UK) and were run in the presence of 1x running buffer (3.5mM 
SDS, 25mM Tris and 0.2M glycine). The gel was visualised using coomassie blue 
stain (0.1% coomassie brilliant blue R-250, 50% methanol and 10% glacial acetic 
acid). 
2.6.1.2 Immobilisation and negative selection against GST 
Glutathione sepharose 4B beads (Pierce, UK) were centrifuged at 400 x g for 2 
minutes and washed with ddH2O three times to remove any ethanol present. To 
purify GST the beads were incubated with the BL21 cell lysate for 60 minutes with 
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shaking at 4˚C. Sepharose beads were centrifuged again and the supernatant was 
removed, before undergoing 3 washes with PBS. 
An amplified aptamer library was negatively selected against GST using the GST 
immobilised sepharose beads. DNA aptamers were prepared as described in section 
2.3.5 and were added to the GST beads, supplemented with selection buffer (1x 
PBS, 5mM MgCl2, 10mM KCl and 0.01% v/v Tween-20) to a final volume of 1ml. The 
mixture was then incubated for 60 minutes at room temperature with shaking, 
before being centrifuged at 1000 x g for 2 minutes; the supernatant was retained 
and kept ready for the positive selection. 
2.6.1.3 Positive selection against immobilised PDE1C 
Purified GST tagged PDE1C, obtained from Genscript (US) was reconstituted in 1x 
PBS (made with ddH2O) to a final concentration of 20µg/ml. N-hydroxysuccinimide 
(NHS) activated dry agarose resin (Thermo Scientific Pierce) was added to PDE1C 
(0.1667g/ml swell volume) and was left to couple at room temperature for 60 
minutes on a rotary shaker. The resin was washed with PBS and centrifuged at 500 
x g, the supernatant was removed before undergoing two more washes. The 
agarose resin was then blocked in 1M Tris for 30 minutes at room temperature on a 
rotary shaker. The agarose resin coupled with PDE1C was washed three times and 
resuspended in selection buffer. Supernatant from the negative selection was 
added to the resin and incubated on a rotary shaker for 30 minutes at room 
temperature. 
Following positive selection, the beads were washed with PBS before being 
resuspended in dH2O and heated to 95˚C for 5 minutes to elute any aptamers. The 
eluted aptamers were then incorporated in to a PCR mastermix, of which 4 aliquots 
(2 reactions and 2 controls) were used to optimise the number of TD-PCR cycles as 
previously described. Once the optimal number of TD-PCR cycles was elucidated, 
the remaining mastermix was amplified before being purified via ethanol 
precipitation. Six rounds of counter-SELEX were performed, initial concentrations of 
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0.02 µg/µl of protein were used, however concentrations were decreased by 0.005 
µg/µl every other round to increase stringency. 
2.6.2 Counter-SELEX against EGFRvIII peptide 
DNA aptamers were identified towards the mutated region exclusive to EGFRvIII. 
Negative selections were produced using EGFR wild type (EGFRwt) protein obtained 
from Life Technologies and aptamers were identified through positive selections 
towards the EGFRvIII peptide (amino acids 6-19; Leu, Glu, Glu, Lys, Lys, Gly, Asn, Tyr, 
Val, Val, Thr, Asp, His, Cys), obtained from Genscript. 
The EGFRwt protein and the EGFRvIII peptide were immobilised as described in 
section 2.5.1.3 using NHS-activated dry agarose resin. For negative selections, an 
amplified DNA aptamer library was incubated with immobilised EGFRwt for 30 
minutes at room temperature on a rotary shaker. The agarose resin was centrifuged 
at 500 x g and the supernatant containing unbound aptamers was administered to a 
positive selection with immobilised EGFRvIII peptide. Following incubation for 30 
minutes at room temperature on a rotary shaker, bound aptamers were eluted by 
heating the resin to 95˚C for 5 minutes. Eluted aptamers were incorporated in to a 
PCR mastermix which was used to determine the optimal number of TD-PCR cycles, 
before the remaining PCR mastermix was used to amplify eluted aptamers. 
Amplified PCR products was purified via ethanol precipitation and entered back in 
to subsequent rounds of selection. Five rounds of counter-SELEX were performed, 
initial concentrations of 0.02 µg/µl of protein were used, however concentrations 
were decreased by 0.005 µg/µl every other round to increase stringency.  
2.7 Establishing aptamer sequences 
2.7.1 Transformation and cloning of identified DNA aptamers 
Once DNA aptamers were selected they were transformed in to chemically 
competent DH5α Escherichia coli (genotype: F- φ80(lacZ)ΔM15 ΔlacX74 hsdR(rk-, 
mk+) ΔrecA1398 endA1 tonA) using a TOPO pCR 2.1 cloning kit (Invitrogen) as per 
manufacturer’s instructions (Fig 2.2). Controls lacked any PCR product within the 
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ligation reaction. Ligated plasmids were added to chemically competent DH5α, 
following incubation for 60 minutes on ice the cells were then heat shocked at 42˚C 
for 90 seconds prior to being snap-cooled on ice for 120 seconds. Transformants 
were spread on to selective LB (63.5mM tryptone, 0.171M NaCl, 0.5% yeast extract 
agar and 10% agar) plates containing 25µg/µl ampicillin, before being incubated 
overnight at 37˚C. 
 
Figure 2.2 – A map of the pCR 2.1 TOPO vector used to ligate aptamers in to, which were 
subsequently transformed in to chemically competent DH5α E.coli and cloned. 
Single colonies were selected and resuspended in dH2O, which was utilised as 
template in a PCR reaction containing M13 primers for colony screening. The PCR 
programme was as depicted in Table 2.5 and PCR products were visualised on a 2% 
agarose gel. Positive transformants were inoculated into LB media containing 
ampicillin before being incubated overnight at 37˚C with shaking. The DH5α E.coli 
cells were harvested by centrifugation at 1000 x g and cloned plasmid was purified 
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using a GeneJET Plasmid Miniprep kit (Thermo Scientific) as per manufacturer’s 
instructions.  
Table 2.5 – Colony PCR programme used to screen for positive aptamer insert. 
Action Time (Seconds) Temperature (°C) 
Initial denaturation 300 95 
Denaturation 30 95 
Annealing 30 45 
Extension 30 72 
Final extension 420 72 
 
2.7.2 Identifying novel aptamer sequences 
Plasmids positive for insert were sequenced by Sanger by Source Biosciences 
(Nottingham, UK) using the M13 primer sites, sequencing used a quality score of 20. 
Aptamer sequences were deduced based on the presence of aptamer primer sites 
(Table 2.3),. Unedited aptamer sequences were analysed by Clustal Omega 
(available: http://www.ebi.ac.uk/Tools/msa/clustalo/) to determine closely related 
sequences based on homology. Families of sequences were re-entered in to Clustal 
Omega to elucidate homologous sequences. Secondary structures of the ssDNA 
aptamers were predicted using MFold software (available: 
http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form). The conditions that 
entered in to MFold were dependent on the type of SELEX performed. 
2.8 Validation of aptamer-target specificity 
Aptamers identified through counter-SELEX, towards EGFRvIII and PDE1C, and cell-
SELEX, towards primary cell cultures were validated through varied methods. 
Aptamers were biotinylated and utilised in a variety of methods, including 
denaturing and non-denaturing western blots, oligohistochemistry and 
aptoprecipitation assays to determine whether the aptamers recognised and bound 
any proteins. 
 45 
 
2.8.1 Preparation of biotinylated ssDNA aptamers for validation studies 
Plasmids, containing required aptamer were used to amplify specific aptamer 
sequences via TD-PCR. The TD-PCR programme used was as in table 3, with 10 
phase two cycles. The aptamers were biotinylated through substituting the forward 
primer within the PCR reaction with a biotinylated forward primer. PCR products 
were pooled and concentrations were determined using a nanodrop 1000, at a 
wavelength of 260nm. Amplified aptamers were denatured by heating at 95˚C for 5 
minutes, before being snap-cooled on ice for 10 minutes to produce ssDNA 
aptamers. The ssDNA aptamers were diluted to 100nM using buffers dependent on 
the validation study. 
2.8.2 Denaturing and non-denaturing Western blot 
For the denaturing Western blot, SVGp12 and U87MG cells were resuspended in 
cold RIPA buffer at 4˚C. The cells were incubated at 4˚C for 60 minutes with shaking, 
before being centrifuged at 16,000 x g for 10 minutes. The supernatant was boiled 
in Laemmli buffer (60 mM Tris, pH 6.8, 10% glycerol, 2% w/v SDS and 0.01% 
bromophenol blue) at 95˚C for 5 minutes. Boiled cell lysates were then run on a 4-
20% gradient Mini-PROTEAN TGX gel (BioRad) in the presence of running buffer (25 
mM Tris, 192 mM glycine and 0.1% SDS). Separated proteins were transferred on to 
polyvinylidene fluoride (PVDF) membrane in the presence of transfer buffer (25 
mM Tris, 192 mM glycine and 10% methanol). The PVDF membrane was blocked in 
TBST buffer (50 mM Tris, 150 mM NaCl and 0.05% v/v Tween-20) containing 10% 
marvel milk powder. Following blocking, the membrane was washed three times in 
TBST for 5 minutes per wash, before being incubated with 100 mM aptamer in TBST 
for 60 minutes at room temperature with shaking. The membrane was washed 
three times, before incubation with Vectastain ABC system as per manufacturer 
instructions. Following another three washes with TBST, aptamer-protein 
interaction was visualised using 3,3’-Diaminobenzidine (DAB) peroxidase substrate 
solution (Dako, UK). 
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Non-denaturing Western blot was performed on cell lines as above with the 
following modifications. SVGp12 and U87MG cells were gently lysed using 0.1% 
Triton X100 in PBS; cells were incubated for 60 minutes with shaking at 4˚C. 
Following incubation, the cells were centrifuged at 16,000 x g at 4˚C, before the 
supernatant was boiled in Laemlli buffer not containing SDS. Proteins within the 
lysate were separated via PAGE in the presence of running buffer without SDS. Non-
denaturing Western blots were also produced for five glioblastoma tissue samples, 
kindly provided by Royal Preston hospital. The tissue samples were already shown 
to be positive for EGFR amplification through the use of the mouse monoclonal 
EGFR antibody (Leica). Tissue samples were homogenised prior to being incubated 
in 0.1% Triton X100 for 60 minutes with shaking at 4˚C. The samples were 
centrifuged at 16,000 x g and the cell lysates were decanted ready for native 
Western blot analysis as previously described. 
 2.8.3 Oligohistochemistry 
Paraffin embedded glioblastoma tissue sections were kindly provided by Royal 
Preston hospital, UK. Tissue sections were immersed in Histoclear for 15 minutes to 
deparaffinise the tissue. The tissue was then rehydrated through graded washes of 
ethanol (100%, 90% and 70%) for 5 minutes each wash. Antigen retrieval was 
performed by immersing the tissue in to 0.01M citric acid (pH 6.0) and heated for 
20 minutes at 97˚C. The tissue sections were allowed to cool by standing at room 
temperature for 30 minutes, before the tissue was incubated with 100nM 
biotinylated aptamer in PBS for 60 minutes at room temperature. The Vectastain 
ABC kit was used to detect aptamer-protein interaction as per manufacturer’s 
instructions. Following three washes with PBS, ABC system was visualised using DAB 
peroxidase substrate solution for 10 minutes. Following three PBS washes, the 
tissue sections were dehydrates through gradual washes of ethanol (70%, 90% and 
100%) before being mounted using DPX mounting media (Sigma, UK). Microscopy 
was produce using a Nikon light microscope. 
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2.8.4 Aptoprecipitation (AP) assay 
SVGp12 and U87MG cells were gently lysed using 0.1% Triton X100 as previously 
described (Section 2.8.2). Streptavidin agarose beads were blocked through 2 hour 
incubation at 4˚C with 0.1% bovine serum albumin (BSA) in PBS, with shaking. 
Biotinylated aptamers (100nM) were added to the native cell lysates, which was 
incubated at 4˚C for 60 minutes with shaking. Once blocked, the beads were 
washed three times with cold PBS (4˚C), before being added to the cell lysate, which 
was incubated for 60 minutes at 4˚C with shaking. Following incubation, the 
streptavidin agarose beads were allowed to settle gravimetrically without any 
centrifuging. The supernatant (input) was removed, and the beads were washed 
three times with cold PBS, each time the beads were allowed to settle 
gravimetrically. Following washes, the streptavidin agarose beads (output) was 
boiled in Laemmli buffer at 95˚C for 5 minutes, the same was produced for the 
input, before the samples were analysed by SDS-PAGE as previously described. The 
SDS-PAGE gel was stained using coomassie blue. 
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Chapter 3: Results and analysis
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3.0  Results 
3.1  Optimisation of DNA aptamer amplification and purification 
The amplification and purification of aptamers, through PCR and ethanol 
precipitation respectively, are important independent procedures within SELEX. 
Non-specific sequences may hinder SELEX selections and reduce the amplification 
of DNA aptamers (Bell and DeMarini, 1991). In-order to increase the specificity of 
aptamer amplification, the PCR protocol was optimised. Inefficient purification of 
the resulting amplified aptamers may lead to the loss of sequences; therefore the 
purification protocol was enhanced to determine the conditions that would 
precipitate DNA aptamers most effectively, which was measured by agarose gel 
electrophoresis.  
3.1.1  Optimisation of DNA aptamer amplification via polymerase chain 
reaction (PCR) 
As minimal biological material was available for SELEX selections, it was important 
that the PCR programme was sensitive and specific enough to amplify the 
respectively small amounts of aptamers that would be eluted. For these reasons, 
touch-down PCR (TD-PCR) was trialled, as it has been previously shown to be more 
specific and sensitive than the standard PCR programme (Korbie and Mattick, 
2008). A touch-down phase (phase one, see table 3.1) was added to the traditional 
PCR programme (phase two), which was optimised and compared with the 
standard PCR programme to validate the additional steps. The standard PCR did not 
utilise the touch-down phase and therefore, only consisted of a total of 30 cycles, 
where as TD-PCR totalled 40 cycles. The phase two cycle was optimised to see the 
number of cycles required without amplifying non-specific sequences. The bands 
produced at different cycle numbers by different PCR programmes were visualised 
by agarose gel electrophoresis and compared to determine which programme 
amplified aptamers most effectively (Fig 3.1).  
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Table 3.1 – The TD-PCR and standard PCR programmes. The TD-PCR consisted of an extra 
10 phase one cycles in which the annealing temperature was gradually reduced 1˚C per 
cycle. The standard PCR did not utilise any phase one cycles and only underwent the phase 
two cycles. 
 Action Temperature (°C) 
TD-PCR 
Temperature (°C) 
Standard PCR 
Initial Denaturation 95 95 
Phase One (10 Cycles) 
Denaturation 95 - 
Annealing 60 (decreased 1°C/cycle) - 
Extension 72 - 
Phase Two (30 Cycles) 
Denaturation 95 95 
Annealing 50 50 
Extension 72 72 
 
Final Extension 72 72 
 
 
Figure 3.1 – Comparison of TD-PCR vs. Standard PCR programme and optimising the 
number of phase two cycles. The optimal number of cycles for the standard PCR 
programme was 15 and 10 for the touch-down programme. The band at 10 cycles of TD-
PCR was sufficiently bright such that the number of cycles may be reduced therefore 
potentially reducing amplification of non-specific sequences. Both gels were pictured using 
the same exposure time and the touch-down stage (phase one, see table 2.3) was not 
shown. Controls (in red) were negative for any amplification. 
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Agarose gels, shown in Fig 3.1, were visualised using the same UV exposure so that 
comparisons could be made. Aptamers, 106bps in length, were amplified after 5 
cycles of both PCR programmes. Non-specific sequences, 150 bps in length, were 
present following 20 cycles of either PCR programme. The intensity of the bands 
corresponds to the amount of DNA that is present, therefore with increased 
amplification there should be an increase in band intensity. The bands with the 
highest intensity were produced by TD-PCR, indicating an increase in aptamer 
amplification using this programme. Based on the agarose gels, 15 cycles of phase 
two amplification was optimal for the standard PCR programme, as further cycles 
would result in the amplification of non-specific sequences. Aptamers were 
amplified following 5 phase two cycles using TD-PCR; however non-specific 
sequences were not seen until 20 cycles. Ten cycles were identified as optimal for 
TD-PCR.  
Comparisons between the two agarose gels were investigated further by 
densitometry analysis using ImageJ software. The density of the 106bp aptamer 
band was determined for each cycle number across both PCR programmes. By 
comparing values generated from ImageJ, ratio change for TD-PCR was calculated. 
A number above 1 showed that there was an increase in aptamer amplification 
using TD-PCR, where as a value below 1 indicated an increase in aptamer 
amplification using the standard PCR programme (Fig 3.2). 
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Figure 3.2 – Ratio change of aptamer amplification, using TD-PCR across varied numbers 
of phase two cycles, in comparison to the standard PCR programme. Values generated by 
ImageJ, based on the density of specific bands at 106 bps, were used to calculate the fold 
change for TD-PCR.  
Values produced by ImageJ showed that TD-PCR produced higher rates of aptamer 
amplification (Fig 3.2), especially between 25 and 30 cycles of amplification. A 2 fold 
increase was observed using 10 phase two cycles, a slight decrease in ratio change 
was observed using 15 cycles. As 15 cycles did not increase aptamer amplification 
significantly and further cycling would result in the production of non-specific 
sequences (Fig 3.3), 10 cycles was determined to be optimal. In accordance with 
these results, the TD-PCR programme was utilised for aptamer amplification and 10 
phase two cycles was used for the initial amplification of the DNA aptamer library. 
3.1.2 Optimisation of DNA aptamer purification via ethanol precipitation 
DNA is insoluble in high concentrations of ethanol, therefore it is commonly used as 
an inexpensive method to precipitate and purify DNA. Commercially available DNA 
purification kits are expensive and may not be efficient when purifying small 
sequences.  In order to maximise the amount of DNA aptamer purified from PCR 
products during SELEX, a modified ethanol precipitation method was trialled and 
compared to the standard method. Modifications of the method included varying 
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the concentration of glycogen and incubation conditions (Table 2.4), as well as 
substituting sodium acetate for ammonium acetate. DNA aptamers were amplified 
by TD-PCR and subsequently pooled, before being aliquoted and purified by the 
aforementioned ethanol precipitation procedures. The resulting pellets of DNA 
were resuspended in the same volume of dH2O and analysed by agarose gel 
electrophoresis (Fig 3.3). 
 
 
Figure 3.3 – Comparison of the standard ethanol precipitation protocol with the modified 
protocol and optimisation of the incubation conditions. Optimal incubation conditions 
were -80 ˚C for 1 hour across both methods of aptamer purification. The optimal glycogen 
concentration was 5 mg/ml showing higher band intensity than that of 10 mg/ml; however 
the standard protocol lacking any glycogen inferred the best method of purification with a 
brighter band. 
A control sample was taken from the pooled PCR products that did not undergo any 
purification; this was taken to determine the level of amplified DNA without 
purification. The majority of the purification methods were sufficient to produce 
bands with higher intensity than that of the loading control, suggesting that DNA 
was purified and concentrated through each method. The exception was the 
standard method with incubation conditions of -20˚C for 24 hours, which showed 
reduced levels of DNA compared to the control suggesting loss of aptamers. The 
modified ethanol method, using a glycogen concentration of 5 mg/ml, with 
incubation conditions of -80 ˚C for 1 hour showed optimal aptamer purification. The 
standard procedure, involved incubation of PCR products at -80˚C for 1 hour and 
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showed a band with similar intensity to that of the optimal improved procedure, 
which utilised 5 mg/ml glycogen and incubation conditions of -80˚C for 1 hour. 
These bands were further analysed using ImageJ software. Values for the varied 
DNA purification methods were taken and compared to that of the loading control 
(Fig 3.4). A ratio change above 1 indicated that the sample was purified and 
concentrated, where as a value below 1 indicated that aptamers were lost. 
 
 
Figure 3.4 – Comparison of DNA purification by the standard procedure and the modified 
procedure, all with varied conditions. Most of the methods tested were successful in 
purifying and concentrating the DNA aptamers, with the exception of the standard protocol 
using glycogen at a concentration of 5mg/ml with incubation conditions of -20˚C for 24 
hours. The standard procedure, with incubation at -80˚C for 1 hour purified the DNA 
aptamers most effectively, with a ratio change of over 2.5.  
Values from ImageJ confirmed the results observed on the agarose gel. The 
standard procedure, where the DNA was incubated at -20˚C for 24 hours resulted in 
two-thirds of the aptamers being lost. All other DNA purification methods were 
able to concentrate the aptamers, with the most effective method being the 
standard protocol, with an incubation at -80˚C for 1 hour, which concentrated the 
aptamers to 2.5 x in comparison to the loading control. The standard procedure, 
incubating at -80 ˚C for 1 hour, was taken forward to maintain the integrity of SELEX 
selections. 
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3.2 Optimisation of cell-SELEX for use on primary cells 
A feature of cell-SELEX is the ability to target a ligand towards biomarkers indicative 
of disease, present on the cell surface. Cell-SELEX is commonly performed on cell 
lines; however some novel biomarkers that exist within primary tissues may not be 
present within cell lines. SELEX selection using whole cells could elucidate novel 
biomarkers whilst also producing a targeting ligand, however the number of cells 
used to select specific aptamers is usually in the hundreds of thousands to millions 
range. If using primary cells, this number of cells may not be available, as short-
term cultures reach confluence slowly, in comparison to cell lines. A cell-SELEX 
procedure that could be used to identify aptamers using small numbers of cells was 
investigated. The cell-SELEX protocol was optimised using cell lines to determine 
the lowest cell number that would return bound aptamers, which could be 
amplified sufficiently. The smallest cell number was then taken through 5 iterative 
rounds of cell-SELEX. The amplification stage, via TD-PCR, was optimised during 
each round by determining the optimal number of TD-PCR phase two cycles.  The 
cycle number which amplified aptamers without amplifying non-specific sequences 
dictated the optimal number of phase two TD-PCR cycles. 
3.2.1 Minimum cell number to return bound DNA aptamers 
Identification of aptamers using a small number of cells would circumvent 
limitations incurred by small amounts of biological material. One round of cell-
SELEX was undertaken using the cell lines SVGp12 and U87MG, eluted aptamers 
were then amplified using the optimised TD-PCR programme (see Section 3.1.2). 
Initially cell-SELEX was performed on a range of cell numbers between 500x103 to 
32x103 cells, and it was shown that aptamers could be amplified through all cell 
numbers tested (data not shown). This was taken further and tested on smaller cell 
numbers, using 32x103 down to 0.1x103 cells (Fig 3.5). 
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Figure 3.5 – Determination of the lowest cell number to return bound aptamer through 
the use of cell lines. Bands were visible across all cell numbers near 100bps, with the 
exception of 2x103 cells. No bands were present within the controls. Increases in 
band intensity can be seen when using 32x103 cells; however saturation occurs 
throughout the bands present thereafter. 
Aptamers were successfully eluted and amplified following one round of selection 
using each cell number. Similar levels of amplification was seen between 16x103 
and 0.1x103 cells, which showed that similar amounts of aptamers were eluted 
from these cell numbers. Aptamers were successfully eluted and amplified from 
100 cells, showing that aptamers may be identifiable using this small number of 
cells. 
3.2.2 Optimisation of amplification during each round of Cell-SELEX using 
minimal cell number. 
Aptamers that are not specific to the target are mainly lost during the first one or 
two rounds of selection, thereby reducing the amount of aptamers that would be 
eluted and entered in to amplification. As template concentration has an effect on 
amplification, 100 cells were used through 5 iterative rounds of cell-SELEX to ensure 
sufficient amounts of aptamer could still be eluted and amplified. The amplification 
stage was optimised during each round of selection, by determining the optimal 
number of TD-PCR phase two cycles; this step was added to maintain the specificity 
of the TD-PCR programme when amplifying small amounts of eluted aptamer (Fig 
3.6).  
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Figure 3.6 – Optimisation of TD-PCR cycle number during 5 iterative rounds of Cell-SELEX 
using 100 cells. The 2 % agarose gels showed 15 cycles of TD-PCR to be universally optimal 
across Cell-SELEX selections, with non-specific bands presenting with increased 
amplification. Phase one cycles were during 0-10 cycles, and phase two cycles were during 
15-40 cycles. The agarose gel for round 5 was inverted to make the bands more visible.  
Figure 3.6 shows 2% agarose gels, used to visualise amplified DNA aptamers from 
five iterative rounds of SELEX using 100 cells. Fifteen phase two cycles of TD-PCR 
were universally optimal, showing one band 106bps in length throughout all 5 
rounds of cell-SELEX selection. Non-specific bands appeared at 150bps with 20 
cycles or more. The agarose gels verified that aptamers could be amplified 
throughout 5 rounds of cell-SELEX using 100 cells. 
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3.2.3 Novel DNA aptamer sequences 
Following five rounds of optimised cell-SELEX using 100 cells, DNA aptamers were 
cloned in to pCR 2.1 TOPO plasmids and positive inserts were checked by colony 
PCR. PCR products were separated on a 2% agarose gel and visualised to determine 
whether positive aptamer inserts were present (Fig 3.7). 
 
Figure 3.7 – Colony screening for positive aptamer insert into pCR 2.1 plasmids. Visible 
colonies were entered in to colony PCR to check for positive aptamer insert. Three colonies 
were positive for aptamer insert, displaying a bright band at 308 bps in length, which 
corresponds to the 106 bp aptamer and 202 bps between the M13 primer sites.  
Following visualisation, three colonies were positive for aptamer insert (Fig 3.8). 
The positive clones were purified by a commercially available kit, and novel DNA 
aptamer sequences were elucidated by Sanger sequencing. Aptamer sequences 
were determined by the presence of the aptamer primer sites or the 
complementary aptamer primer sites (Table 3.2). 
Table 3.2 – Aptamer primer sequences and their respective complementary sequence. 
 Aptamer primers  
(5’ - 3’) 
Complementary aptamers primers  
(3’ – 5’) 
Forward 
sequence 
ATCCTAATACGACTCACTAT  ATAGTGAGTCGTATTAGGAT  
Reverse 
sequence 
 AATTCTGCGGTAAACTCGAGGG CCCTCGAGTTTACCGCAGAATT 
 
Before SELEX selection, the aptamers are present as double stranded DNA prior to 
being denatured in to single stranded DNA; therefore, for each unique aptamer 
within the starting pool, a complementary aptamer sequence also existed. 
Consequently, whether the ‘sense’ aptamer (5`-3`) or the complementary ‘anti-
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sense’ aptamer (3’-5’) was the specific sequence that interacted with the target was 
unknown until validation studies were carried out. Only the M13 forward read was 
sequenced during Sanger sequencing. The assumption that the unknown sequence 
would complement the forward read via Watson-Crick base pairing was taken in-
order to elucidate the M13 reverse sequence (Table 3.3). 
Table 3.3 – Aptamer and complementary aptamer sequences selected towards the 
primary cell cultures U87MG. Primer sites are highlighted in dark red (forward) and light 
blue (reverse), as are the complementary primer sequences which are highlighted in red 
(forward) and blue (reverse). Sequences in bold were elucidated by Sanger sequencing, 
those that are not in bold were elucidated based on complementation to the sequenced 
sense or anti-sense strand.  
Sequence 
name 
Aptamer sequence 
(Sense sequence, 5’-3’) 
Complementary aptamer sequence 
(Anti-sense sequence, 3’-5’) 
U87CLL1 ATCCTAATACGACTCACTATAGG
GAGAGAATTCGTGTGTGTTGCTT
CGGTTTTGGCAAAAGGTTGGAGC
GAAGGGTTGGGCCAGAATTCTGC
GGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCTG
GCCCAACCCTTCGCTCCAACCTTTTG
CCAAAACCGAAGCAACACACACGA
ATTCTCTCCCTATAGTGAGTCGTATT
AGGAT 
 
Three clones were shown to be positive for aptamer insert, however only one 
sequence was able to be sequenced (Table 3.3). As there were no other sequences 
for comparison, Clustal Omega analyses were not performed. 
3.2.4 Structural determination of aptamer sequences. 
Both sense and anti-sense aptamer sequences were entered in to MFold to predict 
secondary structures that the aptamers may conform to. The varied conditions 
entered into the MFold programme were matched to how aptamer selections were 
produced. Prior to selection, the aptamers were denatured and snap-cooled on ice 
to produce single-stranded DNA (ssDNA) aptamers. It was during this step that the 
aptamers folded into three-dimensional structure based on the sequences; 
therefore a temperature of 4˚C was inputted into MFold to match the temperature 
of the snap-cooling process. During the denaturing process, the aptamers were 
contained in a selection buffer containing ions that could impact the aptamer 
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structure. To match the buffer conditions, Mg2+ and Na+ concentrations of 1 mM 
and 5 mM were also inputted in to Mfold. The predicted structures could help 
determine whether aptamers have similar shapes (Fig 3.8). 
 
Figure 3.8 – Predicted secondary structure of novel DNA aptamer sequences selected 
towards U87MG, determined by MFold software.  Primer sites are highlighted, with 
arrows depicting the location of the forward (red) and reverse (blue) primers. 
 
3.3  Identification of DNA aptamers towards primary cells using tailored cell-SELEX 
procedure. 
With the cell-SELEX protocol fully optimised for 100 cells, the methodology was 
applied to primary cultures. Aptamers were negatively selected towards normal 
human astrocyte (NHA) cells and positively selected towards two short-term cell 
cultures, BTNW390 and BTNW914.  
3.3.1 DNA aptamer recovery during each round of Cell-SELEX towards primary 
cultures. 
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Primer
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The aptamer library was amplified before being negatively selected against NHA 
cells; the supernatant was then positively selected towards either BTNW390 or 
BTNW914 glioblastoma short-term cultures. The cell-SELEX procedure was 
performed as previously optimised (Fig 3.6). TD-PCR products were visualised after 
each round of selection to confirm amplification of the aptamer sequences (Fig 3.9). 
 
Figure 3.9 – DNA aptamers following recovery and amplification after each round of Cell-
SELEX selection. Aptamers were eluted and amplified via TD-PCR after each round of 
selection, which was visualised to check aptamers were still present. Round 4 was an 
exception were the aptamers were visualised after purification and not after amplification. 
Bands are present at 106bps throughout each round of selection; however primer dimers 
at 50 bps are visible after round 5. 
Following visualisation by gel electrophoresis, amplified DNA aptamers were still 
present after each round of cell-SELEX selection (Fig 3.9). Amplified aptamers 
eluted from the primary cells after round 5 of cell-SELEX were not purified by 
ethanol precipitation. This was to ensure the DNA aptamers retained the polyA tail, 
added by Taq polymerase, required for cloning into a pCR 2.1 vector.  
Selected aptamers were ligated in to a pCR 2.1 vector and transformed into 
chemically competent DH5α E.coli, before selection on LB agar containing 
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ampicillin. Colonies were subsequently utilised in a PCR reaction to check for 
positive aptamer inserts. PCR products were separated and visualised on a 2% 
agarose gel (Fig 3.10). 
 
Figure 3.10 – Colony screening for positive aptamer insertion into pCR 2.1 plasmid. 
Transformants were checked for positive aptamer insertion into the pCR 2.1 plasmid via 
colony PCR. PCR products were separated and visualised on a 2% agarose gel. Seven 
colonies for aptamers derived against BTNW390 and eight colonies for aptamers derived 
against BTNW914 tested positive for aptamer insertion, displaying a band 308 bps in 
length. Negative colonies (-) for aptamer insertion were observed with bands 
corresponding to the bases between the primer sites within the plasmid at 202bps in 
length. One plasmid displaying a 50bp insertion was shown, this was likely to be a primer-
dimer (PD) produced during amplification within the last round of cell-SELEX. 
Seven colonies tested positive for the aptamer insert, which were isolated from 
cell-SELEX selections using BTNW390 primary cells. Bright bands at 308bps in length 
were observed for these colonies, which was indicative of the length between the 
M13 primer sites (202bps) with the addition of the 106bp aptamer. Eight colonies 
tested positive for the aptamer insert by displaying a band 308bps in length, which 
was isolated through cell-SELEX using BTNW914 short-term cultures. Colonies 
negative (-) for insert (202bps) was observed whilst screening for positive aptamer 
insert isolated against both short-term cell cultures, whilst one plasmid with a 50bp 
insert was only found for BTNW914.   
 
 
 63 
 
3.3.3 Novel DNA aptamer sequences 
The plasmids were sequenced via Sanger sequencing using the M13 forward 
primer. The identified sequences are shown in Table 3.4. Aptamers that were 
identified through the M13 forward read are highlighted in bold and the assumed 
sequences are not in bold. From 7 of the positive plasmids containing aptamers 
derived against BTNW390, one failed to be sequenced. One aptamer, CLL001(U), 
was observed in 57% of isolated plasmids, which were positive for inserted 
aptamers selected towards BNTW390. The same aptamer was also present in 38% 
of positive plasmids containing aptamers selected towards BTNW914. Another 
aptamer, CLL002(U), was found once in plasmids containing aptamers selected 
towards both BTNW390 and BTNW914. Overall one unique aptamer was identified 
towards BTNW390 and four unique aptamers was identified towards BTNW914. 
Two universal aptamers were identified that may be specific to a target found 
within both short-term cultures. 
The sense sequences were put through the Clustal Omega sequence alignment 
software (available: http://www.ebi.ac.uk/Tools/msa/clustalo/) to determine 
similarities between the sequences. The anti-sense sequences were not used for 
Clustal as these sequences are complementary and would reiterate the same 
information. Using information derived from Clustal, possible binding sites and 
positions of importance could be implicated which may allow the aptamer to be 
modified with confidence that the binding would not be impaired. Phylogenetic 
analysis grouped the sequences based on homology, the resulting families of 
sequences were separately analysed by Clustal Omega to elucidate similar 
positions. Sequence alignments were determined using the whole aptamer 
sequence, as possible binding sites may utilise the constant regions for stability. 
Although the primer sites were included with the sequences for analysis, they were 
removed from the diagrams for clarity. 
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Table 3.4 – Aptamer sequences and complementary sequences selected towards the primary cell cultures BTNW390 and BTNW914.  Primer sites are 
highlighted in dark red (forward) and light blue (reverse), as are the complementary primer sequences which are highlighted in red (forward) and blue 
(reverse). Sequences in bold were elucidated by Sanger sequencing, those that are not in bold were elucidated based on complementation to the 
sequenced sense or anti-sense strand. 
Sequence 
Name 
Primary culture 
used for Cell-
SELEX selections. 
Aptamer sequence 
(Sense sequence, 5’ – 3’) 
Complementary aptamer sequence 
(Anti-sense, 3’ – 5’) 
CLL001(U) BTNW390, 
BTNW914 
ATCCTAATACGACTCACTATAGGGAGAGAATTCCACGG
CAGTGTCGTACGGATGAGGAAGTGAAGACGGGGAGGG
AAGGAGTGGAATTCTGCGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCCACTCCTTCCCTCC
CCGTCTTCACTTCCTCATCCGTACGACACTGCCGTGG
AATTCTCTCCCTATAGTGAGTCGTATTAGGAT 
CLL002(U) BTNW390, 
BTNW914 
ATCCTAATACGACTCACTATAGGGAGAGAATTCTCATCC
CCGCGGAAATGACAAAGGACACCGATAACTAGACACCG
TACTCTGAATTCTGCGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCAGAGTACGGTGTC
TAGTTATCGGTGTCCTTTGTCATTTCCGCGGGGATG
AGAATTCTCTCCCTATAGTGAGTCGTATTAGGAT 
CLL003 BTNW390 ATCCTAATACGACTCACTATAGGGAGAGAATTCAGTCAG
GTCACTTATGGTGGGCATAGCTTATTAACATGGTCAAGT
GGTATGAATTCTGCGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCATACCACTTGACC
ATGTTAATAAGCTATGCCCACCATAAGTGACCTGAC
TGAATTCTCTCCCTATAGTGAGTCGTATTAGGAT 
CLL004 BTNW914 ATCCTAATACGACTCACTATAGGGAGAGAATTCAACAGG
GGAGACTAGGATGTGAAATATTGCTGACTAAATGAAAA
GGACCGGAATTCTGCGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCCGGTCCTTTTCATT
TAGTCAGCAATATTTCACATCCTAGTCTCCCCTGTTG
AATTCTCTCCCTATAGTGAGTCGTATTAGGAT 
CLL005 BTNW914 ATCCTAATACGACTCACTATAGGGAGAGAATTCAGTCGG
GTCACTTATGGTGGGCATAGCTTATTAACATGGTCAAGT
GGTATGAATTCTGCGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCATACCACTTGACC
ATGTTAATAAGCTATGCCCACCATAAGTGACCCGAC
TGAATTCTCTCCCTATAGTGAGTCGTATTAGGAT 
CLL006 BTNW914 ATCCTAATACGACTCACTATAGGGAGAGAATTCCCGGT CCCTCGAGTTTACCGCAGAATTCCTGCGATCCCCCTC
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GGTGGGAAAGTGCTCGGGAGGTGGATTGGGGGAGGG
GGATCGCAGGAATTCTGCGGTAAACTCGAGGG 
CCCCAATCCACCTCCCGAGCACTTTCCCACCGGGAAT
TCTCTCCCTATAGTGAGTCGTATTAGGAT 
CLL007 BTNW914 ATCCTAATACGACTCACTATAGGGAGAGAATTCGGTGGT
CCGGAAAAAGCAAGCAAACATGCACGTAAAGAGAAGGA
GCTGCCGAATTCTGCGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCGGCAGCTCCTTCTC
TTTACGTGCATGTTTGCTTGCTTTTTCCGGACCACCG
AATTCTCTCCCTATAGTGAGTCGTATTAGGAT 
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Figure 3.11 – A phylogram of identified aptamers selected towards BTNW390 and 
BTNW914 short-term cultures, by Clustal Omega software. Clustal omega identified three 
different groups based on similarities between the sequences. Aptamers CLL002(U), CLL003 
and CLL005 may share the same target or targets with similar protein configurations; the 
same applies to aptamers CLL001(U) and CLL004. The aptamers CLL006 and CLL007, 
selected against BTNW914, were separated in to their own groups potentially indicating 
different and unique targets compared to the rest of the aptamers.   
 
Figure 3.12 – Consensus sequences displaying similar bases within familial sequences 
identified towards short-term cultures, as determined by Clustal Omega software.  
Following phylogenetic analysis where sequences were grouped into families, the 
sequences were further analysed to determine where similarities are within each 
family. The first family of sequences (A), containing the aptamers CLL002(U), CLL003 
and CLL005, several positions were conserved throughout the group including a 
TAAC sequence located at position 65 to position 68. The second family (B), 
consisting of the aptamers CLL001(U) and CLL004, showed 21 positions with 
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identical nucleotides, including a large AAGGA cluster located at position 76 to 
position 80. 
The Clustal Omega software grouped the novel DNA aptamers in to three different 
families, of which one contained two sub-groups (Fig 3.11). Familial sequences were 
analysed within their sub-group to highlight where similar nucleotides are present. 
Aptamers CLL003 and CLL005 are 99.06% similar (Fig 3.12A), with the only 
difference being a 38G>A single base change within the CLL003 aptamer. CLL002(U) 
was the remaining member of the family and was isolated from cell-SELEX 
selections from both primary cultures. The nucleotide sequence TAAC can be seen 
from position 65 to position 68 within all three aptamer sequences. CLL001(U) 
shares multiple sites of homology with CLL004 (Fig 3.12B), and was isolated from 
individual selections from both primary cell cultures. Similarly to CLL002(U) and 
homologous aptamers CLL003 and 005, the aptamers CLL001(U) and CLL004 may 
bind a common target present on the cell surface of both primary cell cultures.  
CLL006 and CLL007 do not show a significant degree of homology with any of the 
aforementioned aptamers.  
3.3.4 Structural determination of aptamer sequences 
The sense and anti-sense aptamer sequences were entered in to MFold to predict 
secondary structures that the aptamers may produce. The varied conditions 
entered into the MFold programme were matched to how aptamer selections were 
produced. The predicted structures could help determine whether aptamers have 
similar shapes, and therefore determine which share common or unique targets. 
Combined with information from the Clustal Omega sequence alignment software, 
binding sites could also be predicted (Fig 3.13). 
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Figure 3.13 – Predicted secondary structure of novel DNA aptamer sequences selected towards short-term cell cultures and determined by MFold software. Points of 
similarity are highlighted (purple) within the sequences, which was determined using Clustal Omega software. Primer sites are highlighted, with arrows depicting the 
location of the forward (red) and reverse (blue) primers. 
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Figure 3.13 – Predicted secondary structure of novel DNA aptamer sequences, selected towards short-term cell cultures and determined by MFold software. Points of 
similarity are highlighted (green only) within the sequences, which was determined using Clustal Omega software. Primer sites are highlighted, with arrows depicting the 
location of the forward (red) and reverse (blue) primers. 
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Figure 3.13 – Predicted secondary structure of novel DNA aptamer sequences, selected towards primary cell cultures and determined by MFold software. Primer sites 
are highlighted, with arrows depicting the location of the forward (red) and reverse (blue) primers. 
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3.3.5 Validating identified aptamers against primary cells 
From the seven aptamers sequenced, two were chosen to be taken forward into 
validation studies. CLL001(U) and CLL002(U) were picked because these sequences 
were isolated towards both BTNW390 and 914. The aptamers were biotinylated so 
that the ABC system could be utilised to detect aptamer-protein interactions.  
Native cell lysate was prepared from five glioblastoma tissue samples, which was 
analysed by Western blot. The biotinylated aptamers were used to probe the PVDF 
membrane to deduce whether the aptamers interacted with any proteins (Fig 3.14). 
 
Figure 3.14 – Western blot analysis of native cell lysate from five glioblastoma tissue 
samples, using biotinylated CLL001(U) and CLL002(U) aptamers. Native cell lysate from 
five glioblastoma tissue samples were analysed by Western blot and probed with 
biotinylated aptamer to determine aptamer-protein interactions. No specific bands were 
present for either western blot and instead, non-specific staining was observed. 
Following Western blot analysis, no specific interactions were observed for either 
aptamer tested. In contrast, non-specific staining of DAB was observed for both 
Western blots. Further analysis of these aptamers was produced by 
oligohistochemistry using tissue sections of BTNW390 and 914 (Fig 3.15). As these 
were the tissues used to identify the aptamers, they may be specific to a target only 
found on the cell surface of these tissues. 
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Figure 3.15 – Oligohistochemistry using the biotinylated CLL001(U) and CLL002(U) aptamers to detect aptamer-protein interactions within BTNW390 and 
BTNW914 tissue sections. BTNW390 and BTNW914 tissue sections were deparaffinised and probed with biotinylated aptamers derived from SELEX 
selections using short term cultures. Upon visualisation, cells can be seen throughout the tissue samples with brown cell surfaces (arrows), implicating 
aptamer-protein interactions. 
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The tissue sections indicated that the aptamers interacted with a protein on the cell 
surface of cells within the tissue sections. Facilitated by nuclei counterstaining, 
cellular membranes were seen to be more strongly stained brown by DAB, 
implicating aptamer-protein interaction on the cell surfaces.   
3.4 Identification of DNA aptamers towards EGFRvIII peptide through 
tailored counter-SELEX. 
Approximately 44% of glioblastoma cases exhibit EGFR amplification. Three-
quarters of those with EGFRwt over-expressed co-express a truncated EGFR mutant 
that is constitutively active, known as EGFRvIII (Kancha et al., 2013). As the 
mutation is cancer specific, aptamers targeted to the EGFRvIII may offer better 
therapeutic approaches. To identify aptamers specific to EGFRvIII, DNA aptamers 
were positively selected towards and identified against an immobilised EGFRvIII 
peptide. The counter-SELEX procedure was optimised during each round and 
selected aptamers were cloned, before being sequenced and their secondary 
structures predicted. 
3.4.1 Optimisation of DNA amplification via TD-PCR during 6 rounds of 
Counter-SELEX 
DNA aptamers were negatively selected against an immobilised full length EGFRwt 
protein; this was performed to produce aptamers that would specifically recognise 
EGFRvIII by filtering out aptamers that could bind EGFRwt. The remaining aptamers 
that did not bind EGFRwt were positively selected towards immobilised EGFRvIII 
peptide. The peptide can be found between the positions 6-19 within the whole 
EGFRvIII protein and signifies the points at which the 267 amino acid deletion 
occurs, along with a novel glycine insertion. During each round of selection, a small 
fraction of the eluted aptamers was used to optimise the number of TD-PCR phase 
two cycles and determine whether the aptamers were still present. Following 
optimisation of the TD-PCR programme, the remaining eluted aptamers underwent 
amplification and were visualised on a 2 % agarose gel (Fig 3.16).  
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Figure 3.16 – Optimisation of the number of TD-PCR phase two cycles following EGFRvIII 
peptide selection. Amplification was optimal after 13 phase two cycles of TD-PCR during 
rounds 1 and 2, and 15 cycles for rounds of selection thereafter. Amplification of non-
specific bands was detected after 15 cycles for rounds 1 and 2, whereas non-specific bands 
were seen after round 20 for rounds 3, 4, 5 and 6 of EGFRvIII peptide selection. No bands 
were visible in any control lanes; therefore data is shown only for 30 cycles (in red) for 
clarity. Agarose gels for rounds 5 and 6 were inverted to see the bands more clearly. 
Following each round of counter-SELEX, the number of phase two cycles were 
optimised to produce specific sequences 106bps in length, required for enriching 
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the next round (Fig 3.13).  After round 6 of counter-SELEX selection, amplified DNA 
aptamers were ligated in to a pCR 2.1 plasmid and transformed in to chemically 
competent DH5α E.coli. Visible colonies on selection plates were screened to 
identify colonies positive for insert. Colonies were picked and utilised in a standard 
PCR reaction, containing M13 sequencing primers, and visualised on a 2% agarose 
gel. 
 
Figure 3. 17 – Colony PCR screening of chemically competent DH5α E.coli transformants 
for positive aptamer inserts. The agarose gel shows 10 pCR 2.1 plasmids positive for 
aptamer insert, 1 plasmid containing a 50bp primer dimer (PD) and 1 plasmid negative for 
any insert (-). The plasmids positive for aptamer insert corresponds to 308 bases, with the 
aptamer at 106 bases and the distance between the M13 primer sites being 202 base pairs 
long.  
Ten colonies screened positive for aptamer insert, displaying a band at 308 base 
pairs (Fig 3.17).  The bands correspond to the length of the aptamers, 106bps, and 
the sequences in between the M13 primer sites, 202bps. Two negative bands are 
present, one of which may be the result of a primer-dimer being ligated instead of 
aptamers and one where nothing was ligated into the plasmid, indicated by the 
202bp band.  
3.4.2 Identified novel DNA aptamer sequences, selected towards EGFRvIII 
The plasmids positive for aptamer insert were purified through a commercially 
available kit and the sequences were elucidated through the M13 forward primer 
by Sanger sequencing. Sequences were determined by the presence of the aptamer 
primer sites and the complementary aptamers primer sites (Table 3.1).  
The sequences identified by the M13 forward read was used to determine the 
complementary aptamer sequences, based on the assumption that they conformed 
to Watson-Crick base pairing. The sequences are listed in Table 3.3, with the 
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sequences identified through Sanger sequencing in bold. Sense aptamer sequences 
were put through Clustal Omega sequence alignment software to determine if 
there was any similarity between the sequences. 
Table 3.5 – Identified novel DNA aptamer sequences selected towards EGFRvIII peptide 
following 6 rounds of Counter-SELEX.  Primer sites are highlighted in dark red (forward) 
and light blue (reverse), as are the complementary primer sequences which are highlighted 
in red (forward) and blue (reverse). Sequences in bold were elucidated by Sanger 
sequencing, those that are not in bold were elucidated based on the sequenced sense or 
anti-sense strand. 
Sequence Aptamer sequence 
 (5’-3’) 
Complementary aptamer sequence 
(3’-5’) 
EGFRvIII1 ATCCTAATACGACTCACTATAGG
GAGAGAATTCATAGAATGGGGTC
ACGAACGGCACCACACGACACAC
AACATGAATTAAAAGAATTCTGC
GGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCTTTTA
ATTCATGTTGTGTGTCGTGTGGTGCCG
TTCGTGACCCCATTCTATGAATTCTCTC
CCTATAGTGAGTCGTATTAGGAT 
EGFRvIII2 ATCCTAATACGACTCACTATAGG
GAGAGAATTCAAGAAATTAAAC
GACGGATAGACACAAGAAAGGA
TCGAAACTATTTCTCAGAATTCTG
CGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCTGAGA
AATAGTTTCGATCCTTTCTTGTGTCTATC
CGTCGTTTAATTTCTTGAATTCTCTCCCT
ATAGTGAGTCGTATTAGGAT 
 
EGFRvIII3 
ATCCTAATACGACTCACTATAGG
GAGAGAATTCCAGGAAGGAAAA
CAGTAGCGACCTCTAGGAAGGCG
CAGCTAACGCCTACTGAATTCTGC
GGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCAGTA
GGCGTTAGCTGCGCCTTCCTAGAGGTC
GCTACTGTTTTCCTTCCTGGAATTCTCTC
CCTATAGTGAGTCGTATTAGGAT 
EGFRvIII4 ATCCTAATACGACTCACTATAGG
GAGAGAATTCGATACATACCAGC
GCGACTGCAGAGACGAAGGGAA
GGGAACGAAAGCTATGAATTCT
GCGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCATAGC
TTTCGTTCCCTTCCCTTCGTCTCTGAAGT
CGCGCTGGTATGTATCGAATTCTCTCCC
TATAGTGAGTCGTATTAGGAT 
EGFRvIII5 ATCCTAATACGACTCACTATAGG
GAGAGAATTCGGTGGTCCGGAA
CCCTCGAGTTTACCGCAGAATTCGGCA
GCTCCTTCTCTTTACGTGCATGTTTGCTT
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AAAGCAAGCAAACATGCACGTAA
AGAGAAGGAGCTGCCGAATTCTG
CGGTAAACTCGAGGG 
GCTTTTTCCGGACCACCGAATTCTCTCC
CTATAGTGAGTCGTATTAGGAT 
EGFRvIII6 ATCCTAATACGACTCACTATAGG
GAGAGAATTCTCATCCCCGCGGA
AATGACAAAGGACACCGATAAC
TAGACACCGTACTCTGAATTCTG
CGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCAGAGT
ACGGTGTCTAGTTATCGGTGTCCTTTGT
CATTTCCGCGGGGATGAGAATTCTCTCC
CTATAGTGAGTGGTATTAGGAT 
EGFRvIII7 ATCCTAATACGACTCACTATAGG
GAGAGAATTCAGAATGAGGAAAT
AGGTAATCGCAATACGGAATAGG
CCAGATATGACAGGGAATTCTGC
GGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCCCTGT
CATATCTGGCCTATTCCGTATTGCGATT
ACCTATTTCCTCATTCTGAATTCTCTCCC
TATAGTGAGTCGTATTAGGAT 
EGFRvIII8 ATCCTAATACGACTCACTATAGG
GAGAGAATTCGACGCAACGAAA
CGGGGCAGGTATGGTCCGACCG
AGGGACAGAAAAGCAAGAATTC
TGCGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCTTGAT
TTTCTGTACCTCGGTCGGACCATACCTG
CCCCGTTTCGTTGCGTCGAATTCTCTCCC
TATAGTGAGTCGTATTAGGAT 
EGFRvIII9 ATCCTAATACGACTCACTATAGG
GAGAGAATTCAGAAGACAAAGG
ACATAAGAGCTAACCAAGGGTAA
ACGAAGAGGCACAGTGAATTCTG
CGGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCACTGT
GCCTCTTCGTTTACCCTTGGTTAGCTCTT
ATGTCCTTTGTCTTCTGAATTCTCTCCCT
ATAGTGAGTCGTATTAGGAT 
EGFRvIII10 ATCCTAATACGACTCACTATAGG
GAGAGAATTCGAGCGGCTGAATA
AACAAGGAAGCGCTACAAATTTA
AATGAAGACTGCATGAATTCTGC
GGTAAACTCGAGGG 
CCCTCGAGTTTACCGCAGAATTCATGC
AGTCTTCATTTAAATTTGTAGCGCTTCC
TTGTTTATTCAGCCGCTCGAATTCTCTC
CCTATAGTGAGTCGTATTAGGAT 
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Figure 3.18 – Phylogram of identified novel aptamer sequences selected towards EGFRvIII 
peptide, determined by Clustal Omega. Clustal omega grouped the aptamers into three 
separate families with some containing sub-groups. Families and sub-groups were 
produced based on similarities between the sequences.  
 
 
Figure 3.19 – Consensus sequences displaying similar bases within familial sequences 
identified towards primary cultures, as determined by Clustal Omega software. Clustal 
omega highlighted multiple sites of homology within family A. There was no similar 
sequence that was present within all sequences; therefore a possible binding site could not 
be suggested. There were small similarities between the two aptamers within family B and 
a possible binding site may be located between nucleotides 61 to 66. Multiple sites of 
homology are present within family C, including a GAA sequence present in all aptamers 
however was located at different positions in some sequences. 
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Clustal Omega grouped the sequences in to three different families (Fig 3.18); 
families A and C contained further sub-groups. These groups were based on 
nucleotide similarities within the aptamer sequences, as seen in Fig 3.19. Family A 
consisted of four aptamers, from two sub-groups. Similar sequences were seen 
throughout all novel aptamers, including CGA, GAA and CTC segments located at 
similar positions. Although these similarities were seen throughout the family of 
aptamers, no homologous sequence was seen in all aptamers. Family B did not 
present with large segments of similarity, but instead showed multiple positions 
where one or two nucleotides were similar. The largest family, family C, presented 
with many sites of similarity. A GAA was present in all sequences in exact positions, 
with some exceptions, and may represent a sequence of importance. The GAA 
segment within the EGFRvIII5 aptamer was one place out of position, at position 43 
to 45 instead of 42 to 44. The segment was mirrored within the EGFRvIII9 sequence 
with the nucleotide sequence of AAG instead of GAA, as GAA and AAG segments 
were present multiple times for some aptamers. A large segment of GTAAA was 
found in both EGFRvIII5 and EGFRvIII9. This sequence was not present within 
EGFRvIII7; however the mirrored sequence, AAATG, was observed at a similar 
position in the aptamer EGFRvIII10.  
3.4.4 Structural determination of aptamers identified towards EGFRvIII 
peptide 
The sense and anti-sense aptamer sequences were put through Mfold to predict 
the secondary structures the aptamers may conform to (Fig. 3.20). The conditions 
entered in to MFold were as described in section 3.3.4. 
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Figure 3.20  – Predicted secondary structure of novel DNA aptamer sense sequences, selected towards an EGFRvIII peptide and determined by MFold software. Points of 
similarity are highlighted (blue) within the sequences, which was determined using Clustal Omega software. Primer sites are highlighted, with arrows depicting the location 
of the forward (red) and reverse (blue) primers. 
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Figure 3.20 – Predicted secondary structure of novel DNA aptamer sense sequences, selected towards an EGFRvIII peptide and determined by MFold software. Points of 
similarity are highlighted (green) within the sequences, which was determined using Clustal Omega software. Primer sites are highlighted, with arrows depicting the 
location of the forward (red) and reverse (blue) primers. 
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Figure 3.20 – Predicted secondary structure of novel DNA aptamer anti-sense sequences, selected towards an EGFRvIII peptide and determined by MFold software. 
Points of similarity are highlighted (blue and purple) within the sequences, which was determined using Clustal Omega software. Primer sites are highlighted, with arrows 
depicting the location of the forward (red) and reverse (blue) primers. 
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Figure 3.20 – Predicted secondary structure of novel DNA aptamer sequences, selected towards an EGFRvIII peptide and determined by MFold software. Points of 
similarity are highlighted (purple) within the sequences, which was determined using Clustal Omega software. Primer sites are highlighted, with arrows depicting the 
location of the forward (red) and reverse (blue) primers. 
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3.4.5 Validation of novel DNA aptamers, targeted towards an EGFRvIII 
peptide 
Four aptamers from ten were chosen based on dissimilarities and GT content. The 
isolated aptamers, EGFRvIII3, 6, 7 and 8 were biotinylated and further utilised in 
Western blot analyses to determine whether the aptamers interacted with a target. 
Native cell lysate was derived from five glioblastoma tissue samples, all of which 
were positive for EGFR amplification. Whether these samples were EGFRvIII positive 
or not, was unknown. Native cell lysates were analysed by Western blotting and the 
biotinlyated aptamers were used to probe the PVDF membranes (Fig 3.21). 
 
Figure 3.21 – Western blot analyses of native cell lysate from five EGFR amplification 
positive glioblastoma tissue samples.  Native cell lysates from glioblastoma tissue were 
analysed by Western blot. Tissues were EGFR amplification positive, consequently the PVDF 
membrane was probed with EGFRvIII aptamers varying in sequence, to determine whether 
the aptamers would interact with any protein. 
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Native cell lysate from five patients were probed using EGFRvIII different in 
sequence to not only deduce whether the aptamers interacted with a protein, but 
to also determine whether the tissue samples co-expressed the EGFRvIII mutation. 
Western blots using the four EGFRvIII aptamers were all negative, which showed 
the aptamer did not interact with any proteins. 
3.5 Identification of DNA aptamers towards PDE1C through tailored 
counter-SELEX 
DNA aptamers were selected towards purified GST-tagged PDE1C. To prevent cross 
reactivity, negative selections against purified GST and NHS-activated agarose resin 
was produced. PDE1C is not truncated in glioblastoma, but has been shown to be 
over-expressed instead. A negative selection towards a PDE1C analogue was 
therefore deemed unnecessary.  
Identified novel DNA aptamers were biotinylated and used to validate aptamer-
PDE1C binding. Denaturing and native Western blots were performed using SVGp12 
and U87MG cell lysate. Further validation was produced via an aptoprecipitation 
assay, which pulled the aptamer bound target out of the cell lysate for subsequent 
detection. 
3.5.1 Optimisation of DNA amplification via TD-PCR during 6 rounds of 
Counter-SELEX 
An amplified DNA aptamer library was utilised in 6 rounds of Counter-SELEX to 
identify aptamers specific to PDE1C. To circumvent DNA aptamers targeting the GST 
tag bound to the PDE1C, a negative selection against GST immobilised on sepharose 
4b beads was produced. As the NHS-activated agarose resin was used to immobilise 
the PDE1C, negative selections were produced against the resin to prevent the 
aptamers cross reacting with the resin.  
To produce the GST needed for the negative selection, a pGEX-KG vector was 
transformed in to BL21 E. coli. Following GST induction, the cells were harvested 
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and sonicated to produce cell lysate containing the expressed GST. BL21 E. coli cells, 
taken before and after protein expression, were boiled in laemmli buffer and was 
analysed by SDS-PAGE to confirm the presence of expressed GST (Fig 3.22). 
 
 
Figure 3.22 – SDS-PAGE of BL21 E. coli cells before and after GST induction. BL21 E.coli 
was transformed with a pGEX-KG plasmid to produce GST that would be used for the 
negative selection to select aptamer specific to PDE1C. Cells were aliquoted before and 
after GST expression was induced through 100 mM IPTG. The SDS gel showed a surplus of a 
protein, 26 kDa in size, being produced following protein induction, whilst no increase of 
this protein was seen in the control. 
 
Sepharose 4b beads were used to isolate the GST from the cell lysate and the 
subsequent sepharose-GST beads were used for the negative selection of aptamers. 
Unbound aptamers from the negative selection underwent positive selection using 
PDE1C immobilised to NHS-activated agarose resin. Following each round of 
selection, the eluted aptamers were entered in to a PCR mastermix. A portion of 
the mastermix was used to optimise the number of phase two TD-PCR cycles. 
Aliquoted PCR products were separated on a 2% gel and visualised using UV light 
(Fig. 3.23). The remaining mastermix containing eluted DNA aptamers were 
amplified using the optimal number of cycles. 
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Figure 3.23 – Optimisation of the number of TD-PCR phase two cycles following PDE1C 
selection. Amplification was optimal after 20 cycles of TD-PCR during round 1, 10 cycles for 
rounds 2, 3 and 4 and 15 cycles for rounds 5 and 6. Non-specific bands can be seen after 15 
cycles for rounds 2, 3 and 4. Bands were also seen after 20 cycles for rounds 5 and 6, but 
with less intensity than the specific band shown during optimal amplification. No bands 
were visible in any control lanes (in red). All gels were inverted to increase the visibility of 
present bands. 
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Following round 1, the optimal number of phase two cycles was shown to be 20 
cycles. For rounds 2, 3 and 4 the optimal number of cycles decreased to 10 cycles of 
TD-PCR.  Non-specific bands 150bps in length appeared after further cycling at 15 
cycles and upwards. After rounds 5 and 6, the optimal number of cycles increased 
to 15 cycles with increased cycling showing non-specific bands and decreased 
specific aptamer at 106 base pairs in length. 
After the last round of counter SELEX, the amplified aptamers were not ethanol 
precipitated and were instead purified using a commercially available PCR clean up 
kit. Aptamers were ligated in to a pCR2.1 TOPO vector, before subsequent 
transformation in to DH5α E. coli and grown overnight on selection. Visible colonies 
were entered in to colony screening via PCR, amplified products were separated 
and visualised via agarose gel electrophoresis (Fig 3.24). 
 
Figure 3. 24 – Colony PCR screening of chemically competent DH5α E.coli transformants 
for positive aptamer inserts. The agarose gel shows four pCR 2.1 plasmids positive for 
aptamer insert, 1 plasmid containing a 50bp primer dimer (PD) and 1 plasmid negative for 
any insert (-). The plasmids positive for aptamer insert corresponds to 308 bases, with the 
aptamer at 106 bases and the distance between the M13 primer sites being 202 base pairs 
long.   
A total of 17 colonies were shown to be positive for an insert, however only four 
were later shown by Sanger sequencing to have a 106 bp aptamer insert with the 
remaining positive plasmids having non-specific sequences inserted in to the vector 
(see section 3.5.2). Lanes 1 - 4 showed a band indicative of positive aptamer insert, 
at 308 bps long, which corresponded to the 202bps between the M13 primer sites 
and the 106 bp aptamer insert. The insertion of a sequence 50bps in length was 
seen, which was most likely due to the insertion of primer dimers (PD). 
L       1      2      3      4 - PD
400
350
300
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200
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3.5.2 Identified novel DNA aptamer sequences, selected towards PDE1C 
Plasmids positive for inserts were purified from the chemically competent DH5α 
E.coli. The novel DNA aptamers within the pCR 2.1 vector was then elucidated by 
Sanger sequencing. A M13 forward read and a M13 reverse read was produced for 
all positive plasmids. Some sequences identified through Sanger sequencing were 
not 106 bps in length. These non-specific sequences can be found in Appendix 1 
and were not taken further, however the specific aptamer sequences of 106 bps 
can be found in Table 3.6. 
Table 3.6 – Novel DNA aptamer sequences selected towards PDE1C.  Primer sites are 
highlighted in dark red (forward) and light blue (reverse), as are the complementary primer 
sequences which are highlighted in red (forward) and blue (reverse). Sequences in bold 
were elucidated by Sanger sequencing, those that are not bolded were elucidated based on 
complementation to the sequenced sense or anti-sense strand. 
Sequence M13 reverse read M13 forward read 
XApt001 CCCTCGAGTTTACCGCAGAATTCCT
GCGATCCCCCTCCCCCAATCCACCT
CCCGAGCACTTTCCCACCACCGGG
AATTCTCTCCCTATAGTGAGTCGTA
TTAGGAT 
ATCCTAATACGACTCACTATAGGGAG
AGAATTCCCGGTGGTGGNNNNNNGC
TCGGGAGGTGGATTGGGGGAGGGG
GATCGCAGGAATTCTGCGGTAAACTC
GAGGG 
XApt002 CCCTCGAGTTTACCGCAGAATTCA
TACCACTTGACCATGTTAATAAGC
TATGCCCACCATAAGTGACCTGAC
TGAATTCTCTCCCTATAGTGAGTCG
TATTAGGAT 
ATCCTAATACGACTCACTATAGGGAG
AGAATTCAGTCAGGTCACTTATGGTG
GGCATAGCTTATTAACATGGTCAAGT
GGTATGAATTCTGCGGTAAACTCGAG
GG 
XApt003 CCCTCGAGTTTACCGCAGAATTCT
GGCCCAACCCTTCGCTCCAACCTTT
TGCCAAAACCGAAGCAACACACAC
GAATTCTCTCCCTATAGTGAGTCGT
ATTAGGAT 
ATCCTAATACGACTCACTATAGGGAG
AGAATTCGTGTGTGTTGCTTCGGTTTT
GGCAAAAGGTTGGAGCGAAGGGTTG
GGCCAGAATTCTGCGGTAAACTCGAG
GG 
XApt004 CCCTCGAGTTTACCGCAGAATTCC
ACTCCTTCCCTCCCCGTCTTCACTTC
CTCATCCGTACGACACTGCCGTGG
AATTCTCTCCCTATAGTGAGTCGTA
TTAGGAT 
ATCCTAATACGACTCACTATAGGGAG
AGAATTCCACGGCAGTGTCGTACGGA
TGAGGAAGTGAAGACGGGGAGGGA
AGGAGTGGAATTCTGCGGTAAACTC
GAGGG 
 
The aptamer sequences were analysed by Clustal Omega to determine any 
similarity between the sequences. The sequences were grouped in to families 
through phylogenetic analysis to determine which sequences were most alike (Fig 
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3.25). Clustal Omega was also used to determine if there were similar nucleotides 
at similar positions (Fig 3.26), which could help implicate potential binding sites or 
positions of importance. Primer sites were included during Clustal Omega analysis 
but were removed from the diagrams for clarity. 
 
Figure 3.25 – Phylogram of identified novel aptamer sequences selected towards EGFRvIII 
peptide, determined by Clustal Omega.  Clustal omega grouped the aptamers in to three 
separate families. XApt001 and 002 were isolated within their own family showing that 
they are not similar to the other sequences. XApt003 and 004 make up the only family with 
more than one member, displaying some homology between the two sequences. 
 
 
Figure 3.26 – Consensus sequences displaying similar bases within familial sequences 
identified towards primary cultures, as determined by Clustal Omega software. Clustal 
Omega analysis showed that there were multiple positions of similarity, including a 4 
nucleotide sequence of AGGG which could potentially be a binding site. 
Clustal Omega grouped the sequences in to three separate families, two families 
contained one member each (XApt001 and XApt002) and the remaining family 
consisted of two members (XApt003 and XApt004). XApt1 and 2 were not similar to 
the other sequences because they were put in their own separate families. The 
remaining two aptamers were grouped with one another showing they exhibited 
some similarities, which were further investigated through consensus alignment 
profile. There were several regions of similarity between the two DNA aptamers, 
including a four nucleotide sequence of AGGG at position 72 to position 75. These 
positions may represent sites of importance, such as a potential binding site. 
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3.5.3 Structural determination of aptamer sequences, selected towards 
PDE1C 
The identified DNA aptamer sequences were entered in to MFold (Section 3.3.4) to 
predict secondary structures of the aptamers may conform to (Fig 3.27). 
Nucleotides existing in a loop were not usually bound to a complementary base and 
therefore contained positions at which hydrogen bonding with the target may 
occur. The secondary structures for the complementary anti-sense aptamer 
sequences were not predicted. 
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Figure 3. 27 – Predicted secondary structure of novel DNA aptamer sequences, selected 
towards PDE1C and determined by MFold software. Points of similarity are highlighted 
(orange) within the sequences, which was determined using Clustal Omega software. 
Primer sites are highlighted, with arrows depicting the location of the forward (red) and 
reverse (blue) primers. 
3.5.4 Validation of novel DNA aptamers, targeted towards PDE1C 
Identified aptamer sequences were biotinylated and were utilised in an avidin-
biotin complex (ABC) system for detection. The ABC system contained a biotin-
horse radish peroxidase (HRP) complex, which allowed detection through the 
substrate 3,3’-diaminobenzidine (DAB).  
SVGp12 and U87MG cell lysate containing PDE1C was prepared and utilised on a 
Western blot to determine whether the aptamers would bind a protein with a 
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similar molecular weight to that of PDE1C. Biotinylated aptamers were used to 
probe the PVDF membrane to determine whether the aptamer interacted with 
PDE1C, however, only one aptamer (XApt004) showed visible binding (Fig. 3.28). 
 
 
Figure 3.28 – Western blot analysis of cell lysate from SVGp12 and U87MG cell lines, 
using biotinylated XApt004 aptamer.  SVGp12 and U87MG were analysed by Western blot, 
as both cell lines contain PDE1C. The PVDF membrane was probed with biotinylated 
aptamers, however only one aptamer (XApt004) was successful in detecting any protein. 
Two bands, 70 kDa in size was detected and may be indicative of PDE1C. The higher band 
may be the acetylated active version of PDE1C, whilst the lower band is left unmodified. A 
faint band, 90 kDa in size, was also detected and can be explained by the PDE1C isoform 3, 
also present in both cells.  
 
Figure 3.28 showed that the aptamer Xapt004 detected proteins from both cell 
lysates. The two bands around 70kDa suggested detection of PDE1C. The lower 
band of the two is likely to be the inactive form of PDE1C, were as the higher band 
may be the acetylated active PDE1C. A faint band showing the detection of protein 
around 90kDa was seen. This may be an isoform of PDE1C known as PDE1C3, which 
is also present in astrocyte cells. 
Three aptamers did not bind any protein within the cell lysates during Western 
blotting. SELEX selections were performed with a PDE1C protein in native 
conformation; therefore the aptamers were designed to target a native protein and 
not a denatured one. With these considerations in mind, a native Western blot was 
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produced to determine whether the aptamers detected any proteins in their native 
state (Fig 3.29).  
 
 
Figure 3.29 – A native Western blot, using cell lysate from SVGp12 (S) and U87MG (U) to 
show any aptamer-protein binding. Native cell lysate extracted from two cell lines were 
analysed by Western blot and probed using biotinylated aptamer. Most aptamers 
recognised protein from cell lysates, with the exception being XApt002 which did not 
detect protein extracted from XApt002. As XApt004 detected proteins similar to various 
forms of PDE1C, it was considered as a positive control. XApt004 detected two proteins 
from the lysates, which were also detected by other biotinylated PDE1C aptamers, 
therefore all aptamers bound a protein similar to PDE1C but only XApt001-003 could bind 
the native conformation. 
 
By using native conditions for cell lysate preparation, most aptamers were able to 
bind to proteins on the Western blot, as shown by the two brown bands. XApt002 
showed limited aptamer-protein interaction within the SVGp12 cell lysate and 
minimal interaction with the U87MG cell lysate lane when compared to the other 
aptamers used. Some aptamers showed increased staining in the higher band than 
the lower band and vice versa. For instance, XApt001 and XApt003 had an increase 
in staining intensity for the higher band than the lower band. Conversely, XApt004 
showed an increase in staining intensity for lower band than the higher band. 
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Whilst the aptamers have shown they interact with a protein from the cell lysates, 
the molecular weight is unknown because of the absence of SDS. 
The biotinylated aptamers were further used in a procedure known as 
aptoprecipitation (AP). During this protocol, the aptamer binds to the target and 
the complex is pulled out of the protein lysate by utilising the biotin tag, which 
subsequently isolates the aptamer and the bound target. Streptavidin-agarose 
beads facilitated the process, by binding the biotin tag attached to the 5’ end of the 
aptamer. The isolated proteins were then denatured and separated based on 
molecular weight via SDS-PAGE and visualised using coomassie blue (Fig 3.30) 
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Figure 3.30 – Visualisation of aptoprecipitations, utilising biotinylated aptamers to pull out 
the aptamer target from SVGp12 (A) and U87MG (B) cell lysate.  Biotinylated aptamers were 
incubated with cell lysate to bind the aptamer target. The subsequent aptamer-protein 
complex was pulled out of the cell lysate by streptavidin-agarose beads and detected via SDS-
PAGE. The cell lysate used to pull down the aptamer target is denoted as the input (I) and the 
protein target eluted from the aptamer was the output (O). Based on the aptoprecipitations 
for both cell lysates, the aptamers targeted similar proteins of similar molecular weights. 
Bands can be seen around 70 kDa and 90 kDa in a similar configuration to those seen 
previously, a 90 kDa protein indicative of PDE1C isoform 3 (band 1) and two 70 kDa proteins 
indicative of acetylated PDE1C (band 2) and PDE1C not acetylated (band 3). Controls were 
produced separately in the absence of any aptamer (not shown). 
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After visualisation, proteins were seen that were similar to those detected by XApt004 
during the denaturing Western blot. Two bands were visible at 70 kDa and one band at 
90 kDa for most aptoprecipitations. The 90kDa band was not visible for 
aptoprecipitations produced using the aptamer XApt002, using either cell lysate. 
XApt002 was unsuccessful at precipitating any target using the U87MG cell lysate. This 
could either have been caused by a low concentration of the target within the lysate, 
or it could be that the aptamers affinity for the target is low. The most successful 
precipitations were the ones which used the aptamers XApt001, XApt003 and 
XApt004, with all displaying three bands suggestive of two 70 kDa proteins and a 
90kDa protein.  
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Chapter 4: Discussion 
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4.1 Discussion 
Over the last 10 years, personalised treatment regimens, involving surgery, 
radiotherapy and chemotherapy have not significantly improved glioma survival 
rates (Sant et al., 2012, Kohler et al., 2011). Although cancerous cells are more 
sensitive to DNA damaging agents, they lack specificity and may result in unwanted 
damage to healthy tissue producing side effects (Dietrich et al., 2008). There is 
therefore a need for more targeted treatments, with the ability to discriminate 
between healthy and cancerous cells, without producing adverse effects. As part of 
glioma treatment, aptamers may be able to provide specificity where current 
treatments are lacking and deliver therapeutic payloads directly to the tumour in-
order to circumvent therapy associated side effects. This study set out to identify 
novel DNA aptamers that were specific to glioblastoma, through known and 
unknown targets. 
4.2 Producing sensitive and specific cell-SELEX and counter-SELEX 
procedures  
Over the last 24 years, since the first description of aptamer selection by SELEX 
from Gold and Tuerk in 1990, the method has evolved to increase the overall 
efficacy of aptamer identification. One of the first improvements was the 
incorporation of a negative selection, designed to filter out non-specific aptamers 
that may interact with analogues of the specific target (Jenison et al., 1994). This 
early improvement provided the basic foundations on which many different SELEX 
methodologies have been built. Although different, each utilises an amplified 
aptamer library through iterative negative and positive selections, followed by 
amplification, purification and quantification to identify specific aptamers to the 
desired target of choice (Aquino-Jarquin and Toscano-Garibay, 2011). Methods to 
identify aptamers towards cells and purified proteins, through cell-SELEX and 
counter-SELEX respectively were adapted from (Sefah et al., 2010a) and (Navani et 
al., 2009). SELEX involves the iterative application of ssDNA aptamers towards the 
targets, through negative and positive selections. SELEX selections were followed by 
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amplification via PCR, purification via ethanol precipitation and quantification via 
gel electrophoresis. 
4.2.1 Amplification of DNA aptamers by TD-PCR 
Amplification of DNA aptamers via PCR is an important part of the SELEX procedure. 
The initial library entered in to SELEX must be amplified to ensure adequate copies 
are available for aptamer identification. Aptamers eluted from selections must also 
be amplified ready for re-selection during the next iterative round of SELEX. Non-
specific sequences may compete with the aptamers for binding sites and inefficient 
amplification could lead to low numbers of aptamer copies (Sefah et al., 2010a). 
Amplification should be as specific as possible, whilst retaining the ability to expand 
the pool of aptamers. With these considerations a TD-PCR programme was utilised 
to amplify DNA aptamers. 
The TD-PCR programme was produced by the addition of a touch-down phase to 
the standard PCR programme (Korbie and Mattick, 2008). The touch-down phase 
consisted of 10 cycles, starting with an annealing temperature 10˚C higher than 
conventional PCR. By gradually reducing the annealing temperature 1˚C per cycle, a 
population of aptamers was produced with high specificity. The efficiency of PCR is 
highly dependent on the annealing temperature used which is dictated by primer 
melting temperatures (Tm). Primers may partially or non-specifically hybridise to the 
template strand if a low annealing temperature is used, producing unwanted 
products (Bell and DeMarini, 1991). Conversely a high annealing temperature will 
increase the specificity of PCR products, as the primers will only anneal where 
interactions are the strongest and therefore most specific. Although a higher 
annealing temperature decreases PCR artefacts, product yield may be reduced as 
the amount of amplified products is decreased. 
The aptamer population was further amplified by 10 cycles of the second standard 
phase with an optimal annealing temperature of 50˚C. The TD-PCR was more 
efficient than the standard programme, displaying increased amplification of 
aptamers and minimal non-specific amplification despite a higher number of cycles 
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(Fig 3.1).TD-PCR circumvents issues surrounding the annealing temperature by 
utilising two phases for product amplification. The first phase (TD phase) gradually 
reduces the annealing temperature, from high to optimal, progressively producing a 
small population of copies with increased specificity. The second phase amplifies 
these copies under normal optimal conditions, to ensure an adequate yield is 
obtained. In this study, the TD-PCR programme was compared to the standard PCR 
programme through optimising the number of cycles. Too much cycling increased 
the chances of unwanted artefacts and decreased the yield of specific product. Not 
enough cycling produced low amounts of amplification, but reduced artefacts and 
therefore an optimal number of cycles were further investigated. In comparison 
with the standard PCR programme, TD-PCR was shown to maintain a high level of 
specificity whilst increasing the amplification of DNA aptamers.  
Previously TD-PCR has been used in conjunction with asymmetric PCR within SELEX 
to select DNA aptamers towards the H3N2 virus (Wongphatcharachai et al., 2013). 
Asymmetric PCR generates ssDNA aptamers by increasing the ratio of the forward 
primer to the reverse primer, as opposed to the dsDNA aptamers produced by 
standard PCR programmes (Marimuthu et al., 2012). Asymmetric PCR ensures the 
production of ssDNA, were as the dsDNA is denatured and snap-cooled to produce 
ssDNA aptamers. Although the asymmetric PCR is efficient in producing ssDNA 
(Svobodova et al., 2012), by decreasing the ratio of the reverse primer to prevent 
dsDNA from forming, the diversity of the aptamer pool is halved. This is because 
the aptamer pool is lacking adequate copies of the complementary anti-sense 
sequence. Whether the production of ssDNA aptamers is more important than the 
diversity of the aptamer pool is questionable.  
4.2.2 Purification of DNA aptamers via ethanol precipitation 
The stringency of SELEX selections should be controlled, as SELEX selections with 
low stringency could decrease the aptamers affinity to the desired target. To 
control the stringency of SELEX selections, amplified DNA aptamers are purified to 
concentrate the aptamers (Tuerk and Gold, 1990). The purification of aptamers 
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needs to be as efficient as possible to maximise yield and reduce the loss of any 
sequences during the procedure.  
An inexpensive and common method of DNA purification is ethanol precipitation. 
The method works on the principle that DNA is not soluble in high concentrations of 
ethanol. This is normally facilitated by the addition of a salt, which interferes with 
the polar interactions between the DNA and water allowing the oligonucleotides to 
fall out of solution. Ethanol is commonly utilised as it is inexpensive over 
commercial kits, which are prone to inefficient purification as the length of the DNA 
becomes smaller. Kits normally require the addition of isopropanol to reduce the 
loss of small fragments, however this increases the time needed to air dry the 
resulting pellet of DNA to remove residual isopropanol.  
Efforts to improve the purification of DNA aptamers were taken by trialling an 
alternative ethanol precipitation method (Fregel et al., 2010), which used 
ammonium acetate salt at low concentrations and the DNA carrier glycogen. The 
advantages of substituting sodium acetate for ammonium acetate have been well 
documented previously (Crouse and Amorese, 1987). The use of ammonium 
acetate prevents the co-precipitation of dNTPs that are required for amplification, 
as well proteins such as Taq polymerase. Glycogen carries DNA by polar interactions 
with the polar DNA which facilitates purification (Gaillard and Strauss, 1990). The 
addition of glycogen showed no additional benefit when used at either 
concentration of 5 mg/ml or 10 mg/ml. The addition of glycogen did not seem to 
confer any advantage, but could have interfered with DNA-protein interactions as 
previously documented (Gaillard and Strauss, 1990). These interactions are 
necessary for successful aptamer identification and so, the modified methods using 
glycogen was excluded. The standard ethanol precipitation procedure, where the 
mixture was incubated at -80˚C for 1 hour, precipitated the DNA most efficiently. In 
retrospect, DNA precipitation using the standard protocol would still have co-
precipitated dNTPs and other PCR reagents and so, ammonium acetate could have 
been used instead of sodium acetate to circumvent this. 
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4.2.3 Utilisation of minimal biological material for aptamer identification 
4.2.3.1  Minimal cell number for aptamer identification 
SELEX selections are normally produced using a high number of cells, typically they 
are carried out using 1x106 cells (Sefah et al., 2010b, Meyer et al., 2013)Two groups 
have previously utilised the glioblastoma cell line U87MG to identify specific RNA 
and DNA aptamers (Cerchia et al., 2009, Kang et al., 2012). Cerchia et al., identified 
RNA aptamers using 1x107 cells, whilst Kang et al., isolated DNA aptamers using a 
minimum of 1x106 cells. The present study isolated one aptamer following five 
iterative rounds of cell-SELEX, using 100 cells. Although one aptamer was identified, 
whether it is specific or not is still yet to be determined. Additionally, only one 
aptamer was identified, which could imply a limit of detection was reached. Whilst 
this may be the case, this provides a novel route for the use of primary tissues that 
are available in premium amounts.  
Selections are routinely carried out on cell lines as they are more widely available 
than primary tissues. Cell lines are produced by the immortalisation of a cell that 
was once part of a primary tissue; however the patient from whom it was sourced 
does not necessarily ubiquitously express all biomarkers that are indicative of the 
disease. This is especially the case where the tumour is highly heterogenous, 
displaying multiple cell types with varying phenotypes, like glioblastoma. Therefore 
primary tissues may offer a better variety of biomarkers. 
Although primary tissues may be more useful in the identification of novel 
biomarkers, they are only available in small amounts. A surgeon may reduce the 
amount of biopsied tissue or reduce the area that is to be resected to preserve 
higher order functioning brain tissue. Short-term cultures established from primary 
tissue often grow slowly. The cells may acquire mutations as a consequence of cell 
culture, leading to aptamers targeting biomarkers that are non-specific (Sampson et 
al., 2000). The use of primary tissue may also allow for personalised treatments; 
however quick aptamer identification would be required to prevent mortalities.  
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To facilitate aptamer identification to 100 cells, TD-PCR programme was optimised 
during each round, by determining the most efficient number of phase two cycles 
required for aptamer amplification. Despite using a small number of cells, aptamers 
were still present following 5 rounds of selection. Aptamers identified using a small 
number of cells may have better binding affinities than aptamers isolated using 
large cell numbers. There would be a limited number of targets using small cell 
numbers and therefore, stringency is increased as a consequence of heightened 
competition for binding sites.   
4.2.3.2 Minimal amount of protein for aptamer identification 
Aptamers can be targeted towards proteins indicative of disease by exposing an 
aptamer library to immobilised purified protein or peptide. Purified proteins or 
peptides may be purchased commercially, although they can be expensive, 
therefore, there is a requirement for a counter-SELEX procedure that is able to 
identify aptamers using minimal amounts of protein. Hicke et al., identified 
aptamers towards DNA aptamers towards tenascin-C, which is over-expressed in 
tumorous cells (Hicke et al., 2001). Specific aptamers were isolated following eight 
rounds of selection, however the group did not document the amount of protein 
used for each round. The smallest amount of protein utilised for selection was 
15ng/µl for aptamers identified towards PDE1C during rounds 5 and 6 of SELEX. 
Similar to the previous cell-SELEX procedure, TD-PCR was tailored for each round of 
counter-SELEX selection. Whilst DNA aptamers were identified towards PDE1C, a 
high amount of non-specific DNA sequences were present within the final pool of 
aptamers at round 6 (not shown). This was problematic when cloning; many 
colonies entered into colony PCR showed non-specific insertions within the 
plasmid. Most of the non-specific sequences were 50-90bps in length and were 
likely to have been the result of primer-dimer formation (Roux, 1995). The presence 
of primer-dimers indicated a low concentration of template. Rather than 
hybridising to the aptamer template, a forward primer non-specifically binds to a 
reverse primer and Taq polymerase initiates amplification of small sequences. In-
order to prevent this from happening in future counter-SELEX procedures, the 
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primer concentration could be lowered to prevent dimerisation. Alternatively, 
aptamers could be cloned during an earlier round when the aptamer concentration 
is higher. 
The incorporation of capillary electrophoresis (CE-SELEX) during counter-SELEX 
could also have been used to improve aptamer identification towards purified 
proteins, by increasing the enrichment efficiency following each round (Mosing et 
al., 2005). CE-SELEX separates aptamers bound to the target from free aptamers 
based on different electrophoretic profiles. Aptamers are eluted from the fraction 
containing aptamer-bound target, which is amplified and incorporated back in to 
the following round of selection. CE-SELEX also decreases the presence of non-
specific aptamers that may be present after elution, this results in selective 
aptamers being amplified by PCR. The amplified aptamers are then reincorporated 
back in to following rounds, producing SELEX selections with a high rate of 
enrichment. Mosing, et al., (2005) used CE-SELEX to identify aptamers towards HIV-
1 reverse transcriptase in four rounds of selection. They noted that aptamers were 
usually selected in 8-12 rounds of standard SELEX, whilst highly specific and 
selective aptamers were selected in a much smaller number of iterative rounds. 
Consequently, by reducing the number of SELEX rounds, the amount of biological 
material needed for aptamer identification was also reduced, therefore, the 
incorporation of CE-SELEX may help identify aptamers to a protein target whilst 
reducing the amount of purified protein needed. 
4.3  The identification and validation of DNA aptamers towards short-term 
cultures  
Aptamers are routinely identified using cell lines and have been identified to 
numerous cancer cell lines such as leukaemia (Shangguan et al., 2006), lung cancer 
(Chen et al., 2008) and prostate cancer (Lupold et al., 2002). Previously, two groups 
have selected aptamers towards the glioblastoma cell line U87MG. Cerchia et al., 
isolated RNA aptamers towards the U87MG cell line where as Kang et al., identified 
DNA aptamers (Cerchia et al., 2009, Kang et al., 2012). Whilst the nucleotide basis 
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of library was different, the basic foundations to select aptamers to the target cells 
were very similar, as both utilised a negative selection to filter non-specific 
sequences in-order to potentiate the identification of specific aptamers to a target 
(Sefah et al., 2010a).  
In the present study, a DNA aptamer library underwent a negative selection of NHA 
primary cells to identify selective and specific aptamers to primary glioblastoma 
cells derived from patient biopsies. The main aim of this study was to determine 
whether biopsy samples could be utilised to generate novel aptamers. 
4.3.1 Aptamers identified towards primary cells 
A total of 7 unique aptamers were identified towards BTNW390 and BTNW914 
primary cells in the present study. Elucidated sequences were analysed though 
Clustal omega to group the aptamers based on similarity. Clustal omega grouped 
the aptamers in to four separate families (I-IV), with two aptamers (CLL006 and 
CLL007) showing no similarity to any other aptamer and therefore, were separated 
into their own family (Table 4.1). 
Table 4.1 – Families of aptamers derived against primary cells, based on sequence 
similarities as determined by Clustal omega. 
 Family Aptamer name 
Primary culture used for cell-
SELEX selection 
I CLL002(U) BTNW390, BTNW914 
 CLL003 BTNW390 
 CLL005 BTNW914 
II CLL001(U) BTNW390, BTNW914 
 CLL004 BTNW914 
III CLL006 BTNW914 
IV CLL007 BTNW914 
 
Each family was further analysed by Clustal Omega to elucidate which positions 
were similar. Whilst the information gained was used to predict sequences of 
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interest for five aptamers, the remaining two were not analysed further because 
they were not similar to any other sequence. MFold was used to predict the 
secondary structures of all sequences, including the sense strand and the anti-sense 
strand, to determine whether similar sequences produce similar shapes, but also to 
determine whether homologous sequences were present within stem loops or not. 
A 65-TAAC-68 sequence was synonymous throughout family I members. The 
homologous sequence was contained within a stem loop for all family members 
and therefore, could represent a potential binding site for the target. CLL003 and 
CLL005 were almost identical to one another, with the only difference being a single 
base change at position (A38G). Due to the high similarity between the two 
aptamers, it was likely that both aptamers targeted the same protein, which may be 
found in both short-term cultures, as observed for CLL002(U) which was isolated 
from both BTNW390 and BTNW914 primary cells. All of these findings also hold 
true for the anti-sense strands, which are complementary to the sense strand. 
Family II exhibited multiple sites of homology, including 53-TGA-55, 65-GAC-67 and 
76-AAGGA-80. Based on the predicted secondary structures, the short TGA 
sequence was contained within stem loops for all family members and may 
represent a binding site or a site of importance. The GAC sequence was also present 
within CLL001(U); this was similar for CLL004 with the exception of the adenine 
nucleotide being part of a stem loop. It is likely that this sequence is not a possible 
binding site, but rather a site of importance that is either important to the overall 
aptamer structure or confers some stability when bound to the target. Similarly, the 
AGGAA sequence is predicted to be part of a stem loop for CLL001(U), however for 
CLL04 the adenine at position 76 was part of a stem loop and 79-GA-80 was part of 
a different stem loop, whilst the 78-AG-79 segment was in a similar position. 
Although different for each sequence, the structures are not exact and may 
represent a binding site or site of importance. 
CLL001(U) from family II and CLL002(U) from family I may offer better affinities than 
the other aptamer sequences. The number of times an aptamer is sequenced 
correlates to the number of copies within the aptamer pool from which it was 
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cloned (Ellington and Szostak, 1990). If there is a higher concentration of one 
aptamer sequence following multiple rounds of selection, it can be postulated that 
the aptamer has better binding characteristics for the target. CLL001(U) was 
sequenced from 50% of plasmids with aptamer insert and may have better binding 
characteristics than other family II members. Similarly, CLL002(U) was sequenced 
from 14% of positive clones and may have better binding characteristics than other 
aptamers within family I. 
4.3.2 CLL aptamers in comparison to DNA aptamers derived against the 
U87MG cell line 
During a previous study within the group, DNA aptamers were selected towards the 
cell line U87MG. The aptamer library was identical to the one used in the present 
study and a number of aptamers were isolated and sequenced. Overall, out of 10 
positive clones, 7 aptamer sequences 106bps in length were identified towards 
U87MG and were denoted U87TDM. The U87TDM aptamers were compared to the 
CLL aptamers derived against short-term cell cultures to check for any homology 
between the sequences. Homologous sequences could imply that the aptamers 
target similar biomarkers; conversely, any dissimilar CLL sequences could implicate 
aptamers that target novel biomarkers not present in the glioblastoma cell line. 
Sequence homology was determined as previously performed; Clustal Omega 
software grouped the sequences based on similarities (fig 4.1), before individual 
groups were further analysed to elucidate the similar positions between the 
sequences (fig 4.2). Any groups that contained only CLL aptamers or only U87TDM 
aptamers were ignored. 
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Figure 4.1 – A phylogram grouping CLL aptamers and U87TDM aptamers based on 
sequence similarities, as determined by Clustal Omega software.  The aptamer sequences 
were grouped in to 3 large families, which contained numerous sub-groups based on the 
extent of similarities between the aptamers. CLL aptamers and U87TDM aptamers were 
present in the majority of groups, showing that homologous sequences were present 
between the aptamers, which were isolated from primary cells and cell lines respectively. 
CLL003 and CLL005 were not grouped with any U87TDM aptamers, but instead resided 
within their own family.  
 
 110 
 
 
Figure 4.2 – Consensus sequences between familial CLL and U87TDM aptamers, 
determined by Clustal Omega software.  Phylogenetic analysis identified sequences that 
were similar; these were subsequently entered through Clustal Omega separately to 
highlight conserved regions. Conserved regions are highlighted in red boxes. U87TDM2 was 
included in sub-group III as it was deemed to have sufficient homology with the other 
aptamers within the group, indicated by the length of the line before the sequence 
branched off. U87TDM7 was not included in sub-group IV because it did not contain 
sufficient homology with the other aptamers within the sub-group and therefore, could 
have skewed the results. CLL003 and 005 were ignored because they were not similar to 
any U87TDM aptamers. 
 
Phylogenetic analysis showed many CLL and U87TDM aptamers to be related. The 
aptamers CLL006 and CLL007 did not show any similarity to any other aptamer 
selected towards short-term cultures, however Clustal highlighted similarities 
between them and some of the U87TDM aptamers. CLL006 had multiple sites of 
homology with U87TDM1, including a large 64-CGTA-77 conserved region, which 
could implicate the sequence as a potential binding site or site of importance. 
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CLL006 was paired with three U87TDM aptamers, although it shared most 
homology with U87TDM10 with conserved regions of 34-CCG-36 and 41-TGGG-44. 
Interestingly, CLL002(U) was no longer grouped with CLL003 or CLL005 and was 
instead grouped with U87TDM6 as the two sequences shared more homology, than 
CLL002(U) did with CLL003 and CLL005. The aptamers CLL002(U) and U87TDM10 
shared conserved regions of 54-AAGG-57 and 68-CTAG-71. As Clustal Omega could 
not recognise a significant amount of homology between CLL003/CLL005 and any of 
the U87TDM aptamers, they may target a biomarker that was present in either 
primary cultures used, which are not present in the U87MG cell line. 
4.3.3 Validating target interaction using aptamers identified towards short 
term cultures 
The aptamers CLL001(U) and CLL002(U) were tested to determine whether they 
interacted with any target. Native cell lysate was extracted from five tissue samples, 
which were biopsied from patients with grade IV glioblastoma. The protein extracts 
were analysed by Western blotting and biotinylated sense aptamer was used to 
probe the PVDF membrane. 
The results of the Western blot were inconclusive. Whilst a brown band was 
observed for each patient sample, the banding was erratic and could have 
suggested that there were non-specific interactions. Conversely, banding may have 
been erratic because of the absence SDS, which binds the proteins to give it a 
negative charge. A negative charge would allow the protein to be separated based 
on size without the charge of the protein having an effect. These results require 
further investigation to determine whether these and other CLL aptamers bound to 
a target or not. If the bands were a byproduct of non-specific interactions, then the 
sense aptamer may not be the selective aptamer that targets the protein, instead 
the selective and specific aptamer may be the anti-sense sequence. Whilst 
biotinylating the aptamer aids in acknowledging aptamer-protein interaction, it 
cannot be ruled out that biotinylation perturbed the aptamer from interacting with 
the target protein.  
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Oligohistochemistry using glioblastoma tissue sections provided mixed results. 
CLL001(U) aptamer-protein interaction was evident for BTNW914 which distinctly 
stained the cell membrane brown. Staining was not as apparent for the remaining 
tissue slides prepared, nonetheless this implied that the aptamers targeted and 
bound a protein present on the cell surface. Conversely, background staining 
caused by naturally occurring biotin cannot be ruled out. Other appropriate 
validation studies may be helpful in determining aptamer-target interaction, such 
as localisation studies using fluorescently labelled aptamers instead of biotinylated 
aptamers. 
4.3.4 Utilising primary cells to identify novel aptamers 
To the best of the author’s knowledge, this is the first time primary cells extracted 
and cultured from humans have been utilised in-order to identify aptamers. A cell-
SELEX protocol using 100 cells per cycle was produced utilising cell lines. This 
showed that aptamers could be identified on a minimal amount of starting tissue 
such as cells from a biopsy, and in fact in the future short-term culture of the biopsy 
material may not be required. Whilst this means that a biopsy is required, which 
still carries inherent risks, the amount of tissue excised could be minimalised. 
Whilst this study is the first example to use primary human cells in short-term 
culture within cell-SELEX, another SELEX methodology, known as tissue-slide SELEX, 
utilises primary tissue minimally  in-order to identify selective and specific aptamers 
(Li et al., 2009). Tissue-slide selection uses thinly sliced paraffin embedded tissue 
sections to identify aptamers to intracellular as well as extracellular biomarkers. Li 
et al., used tissue-slide SELEX to identify ssDNA aptamers to breast cancer tissue, 
following 12 rounds of selection one specific aptamer, BC15, was identified. 
Although aptamer identification is dependent on efficient removal of paraffin and 
antigens being retrieved effectively (Shi et al., 2006), it may provide a more 
effective route to personalised aptamers as the tissue can be mapped to determine 
whether whole tissue sample is cancerous or not. If non-cancerous cells are still 
present, non-specific aptamers may be produced which could potentiate 
therapeutic associated side effects. Both methods offer various advantages and 
 113 
 
disadvantages towards personalised therapeutic regimens involving aptamers. The 
best method of aptamer identification may involve a combination of both; however 
any aptamers selected would still require testing to determine whether they are 
specific, tolerable and whether they are internalised in to the target cells in order to 
deliver chemotherapeutic payloads. 
4.4 The identification and validation of DNA aptamers towards EGFRvIII 
peptide 
The EGFRvIII mutant receptor is an attractive candidate for ligand targeting because 
the molecular aberration is cancer specific and has not been observed in healthy 
tissue (Sok et al., 2006). Monoclonal antibodies have been produced that 
specifically target EGFRvIII without cross-reacting with EGFRwt, however none have 
been approved for clinical use thus far (Sampson et al., 2000). Previous attempts to 
select aptamers towards this truncated protein have thus far shown mixed results, 
with two groups selecting RNA and DNA aptamers that cross-react with the wild 
type equivalent (Liu et al., 2009, Li et al., 2011). In the present study, a DNA 
aptamer library was negatively selected against EGFRwt to mitigate or ameliorate 
aptamer cross-reactivity. A peptide indicative of the mutated region (amino acids 6-
19) was employed as the target epitope during positive selection and 10 novel DNA 
aptamer sequences were identified. 
4.4.1 Aptamers identified towards EGFRvIII peptide 
Ten DNA aptamers were isolated towards the EGFRvIII peptide, all with unique 
nucleotide sequences. Clustal Omega software was used to group the sequences 
based on sequence similarities which were further elucidated by analysing the 
families individually. The EGFRvIII aptamers were grouped in to 3 large families 
(Table 4.2). 
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Table 4.2 – Families of aptamers derived against EGFRvIII peptide, based on sequence 
similarities as determined by Clustal omega. 
Family Aptamer name 
Family A EGFRvIII1 
 EGFRvIII2 
 EGFRvIII6 
 EGFRvIII8 
Family B EGFRvIII3 
 EGFRvIII4 
Family C EGFRvIII5 
 EGFRvIII7 
 EGFRvIII9 
 EGFRvIII10 
 
EGFRvIII DNA aptamer sequences within family A displayed multiple homologous 
sequences including 62-CGA-64, 75-GAA-77 and 80-CTC-82. All of which could imply 
sites of importance, however no single conserved sequence was observed 
throughout all aptamers within the group. Whilst this could be explained by the 
aptamers having multiple sites in which the EGFRvIII peptide could bind, it was 
unlikely because there were no similarities between the conserved regions. 
Conversely, it could be that none of these conserved regions bind the peptide and 
instead, serve the aptamer by increasing aptamer-peptide stability when bound. 
The adenine nucleotide at position 64 was synonymous through all members within 
family A, and could potentially be the nucleotide which interacts with the EGFRvIII 
on its own. 
Family B consisted of two EGFRvIII aptamers; EGFRvIII3 and 4, which displayed 
multiple sites of homology that were one or two nucleotides long. As these 
similarities consist of a small number of nucleotides, it was difficult to predict a 
potential binding site. Nevertheless, the 61-GNANGG-66 region could be a possible 
binding site, as these similarities were predicted to be present within a stem loop 
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and could implicate multiple positions in which the aptamer interacts with the 
peptide target. 
Four EGFRvIII DNA aptamer sequences were grouped in to family C. Similar to 
family A, Clustal Omega determined multiple sites of homology to be present 
between the sequences; however no single conserved sequence was present 
throughout all sequences within the group. An adenine and thymine nucleotide was 
synonymous at positions 51 and 66 respectively, throughout all EGFRvIII aptamers 
within the family. These positions could potentially be the binding site in which the 
aptamer interacts with the EGFRvIII peptide. 
No single sequence from any family was observed more than once during 
sequencing from clones displaying positive insert. An explanation for this could 
have been that the counter-SELEX selections were not stringent, even though the 
concentration of the peptide was decreased in an attempt to increase stringency. 
This was not enough to make the selections competitive and the resulting 
sequences could potentially have low affinity to the peptide target. 
4.4.2 Validating target interaction using aptamer identified towards 
EGFRvIII 
Four aptamers were chosen from differing families based on GT content which has 
implications on the aptamer stability. A high GT content will give the aptamer an 
advantage as it is more stable because of the increased number of hydrogen bonds 
that can occur. Native cell lysate from five glioblastoma tissue samples were 
analysed via Western blot, which were subsequently probed with each biotinylated 
sense aptamer. 
Western blot analyses did not show any interaction between the biotinylated 
aptamers sense sequences and the EGFRvIII peptide, in both denaturing and non-
denaturing conditions. Similar to the CLL aptamer validation studies, biotinylation 
could have altered the aptamers conformation or blocked the aptamer binding site, 
leading to no interaction being observed. Whilst this may be the case, the specific 
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and selective aptamer may not be the sense sequence, but could potentially be the 
anti-sense sequence instead. All five patients were EGFR amplification positive, 
whilst it is plausible that the tissues did not contain the EGFRvIII mutation, it was 
unlikely as 75% of patients that exhibit EGFR amplification also co-express the 
truncated variant.  Further studies are therefore warranted to determine if the 
aptamers target EGFRvIII, such as surface plasmon resonance (SPR) or 
electrophoretic mobility shift assay.  
4.4.3 EGFRvIII specific aptamers in glioblastoma therapy 
EGFRvIII is an attractive target as it is unique expressed in glioblastoma and not 
healthy tissues, drastically reducing the chances of collateral damage and 
subsequent side effects (Sok et al., 2006). Previously selected aptamers that target 
both EGFRvIII and EGFRwt have shown the protein to be internalised and degraded 
more efficiently upon aptamer inhibition (Li et al., 2011). Whilst these effects would 
undoubtedly increase positive outcomes within a therapy regimen, the protein may 
not be ubiquitously expressed throughout the tumour cell population. Lopez-Gines 
et al., studied EGFR amplification levels in gliobastoma patients and saw that some 
patients displayed multiple copies of the gene in as less than 1% of cells tested. As 
EGFR amplification is a pre-requisite for the EGFRvIII version to be present (Luwor 
et al., 2004), not all of the cells may express the aberration. 
4.4  The identification and validation of DNA aptamers towards PDE1C 
PDE1C offers another attractive candidate for targeting as the enzyme has been 
shown to be upregulated in glioblastoma as a consequence of gene amplification 
(Rowther et al., 2012). Upon inhibition, cells become less mitogenic and growth is 
slowed. PDE1C is an intracellular second messenger that cleaves cAMP and cGMP to 
AMP and GMP respectively (Goraya and Cooper, 2005). The reaction is produced in 
a calmodulin-dependent manner that concludes with metabolic effects. Previous 
studies have shown PDE1C upregulation to correlate with proliferative behaviour; 
therefore inhibition of this target may lead to a significant survival advantage 
(Rowther et al., 2012). 
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To the best of the author’s knowledge, this is the first time aptamers have been 
targeted to PDE1C. A negative selection of GST was produced to circumvent 
aptamers non-specifically targeting GST-tags fused with the full length PDE1C 
protein, which was utilised during positive selections. 
4.4.1 Aptamers identified towards PDE1C 
From seventeen clones positive for aptamer insert, 4 unique DNA aptamer 
sequences were isolated through counter-SELEX towards PDE1C. Clustal Omega 
determined that two of these sequences were related by similar nucleotides at 
similar positions, whilst the other two were segregated in their own families 
showing that they were not similar to any of the other sequences (Table 4.3). 
Table 4.3 – Families of aptamers derived against EGFRvIII peptide, based on sequence 
similarities as determined by Clustal omega. 
Family Aptamer name 
Family A XApt001 
Family B XApt002 
Family C XApt003 
 XApt004 
 
Families A and B only consisted of one aptamer and as there was no other 
sequences similar to these two sequences, they were not analysed further. XApt003 
and XApt004 were grouped together because they contained regions that were 
conserved throughout either sequence. The longest sequence conserved 
throughout both PDE1C aptamers was 72-AGGG-75, however there are multiple 
regions of homology that are close to one another from position 58 to 79. This 
could imply that the aptamers binding site was located within this particular 
segment of the sequence, as it was likely that there are many positions that interact 
with the target. 
Most of the clones that showed positive for aptamer insert were in fact non-specific 
sequences, likely to have been produced during amplification by TD-PCR. This 
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suggested the counter-SELEX selections were too stringent and too many iterative 
rounds were produced, as aptamers were lost and non-specific products dominated 
the aptamer pool. This was not apparent using gel electrophoresis to qualitatively 
assess the amount of aptamers still present. Increasing the concentration of protein 
during selection would have circumvented this, as would a decrease in the number 
of iterative rounds produced.  
4.4.2 Validating target interaction using aptamer identified towards PDE1C 
PDE1C is present within astrocytic cell lines, consequently cell lysate from SVGp12 
and U87MG were extracted and analysed by Western blot. The sense sequence of 
all PDE1C aptamers selected was biotinylated and used to probe the PVDF 
membrane that contained denatured proteins from the cell lines. Upon 
visualisation, only one aptamer, XApt004, detected proteins were as no signal was 
shown for the remaining aptamer sequences. XApt004 detected three proteins 
which are thought to be similar in molecular weight. The XApt004 aptamer 
interacted with two proteins both of which were 70kDa in size. The lower band at 
70kDa was indicative of the inactive PDE1C protein, whereas the higher band was 
the active PDE1C which is acetylated at amino acid position 1. Furthermore, a 
90kDa protein was detected; this protein may be the PDE1C isoform 3 which is also 
present in astrocytic cells (Yan et al., 1996). The band for PDE1C isoform 3 was faint 
indicating cellular levels of this protein may be low or the aptamer may not bind 
efficiently to this spliced variant. These results are similar to those produced by 
Giachini et al., who studied PDE1C over-expression in hypertensive rats. Using a 
PDE1C antibody, a similar pattern was observed with two proteins 70 kDa in size 
being detected and a 87 kDa protein being detected (Giachini et al., 2011). The 
PDE1C isoform 3 was smaller because of the difference in species. 
PDE1C aptamers were derived using purified protein in a native conformation; 
therefore XApt001-003 should only bind to the native configuration and not the 
denatured configuration. With this in mind, SVGp12 and U87MG cells were gently 
lysed in native conditions. Subsequently analysis by non-denaturing Western blots 
showed that these aptamers did indeed bind a protein indicative of PDE1C. 
 119 
 
XApt004 was shown to interact with proteins similar in size to various forms of 
PDE1C and so, the aptamer was utilised as a positive control. A high and a low band 
were observed for all aptamers successful in detecting protein from the native cell 
lysates, including the XApt004 positive control, therefore it can be concluded that 
all aptamers may bind the second messenger PDE1C. XApt002 was not as successful 
as the other aptamers in detecting the PDE1C than the other aptamers. Aptamer-
protein interaction was minimal using native U87MG cell lysate and no bands were 
present using native cell lysate from SVGp12. In comparison to the Western blot 
under denaturing conditions, the detection of one band was lost as only two bands 
was detected wereas three bands were detected during the denature Western blot. 
This could either have been caused by the non-denaturing conditions having a 
detrimental effect, as the charge is an added factor when these conditions are 
used, or the aptamers may not recognise the natural configuration of the protein. 
An aptoprecipitation (AP) method was used to pull out the biotinylated PDE1C 
aptamer bound target out of the cell lysate extracted under native conditions. 
Isolated proteins were analysed via SDS-PAGE and visualised using coomassie blue 
staining. Upon visualisation, three bands were observed for most aptamers, with 
two 70 kDa bands and one 90 kDa bands, which was a similar configuration to that 
of the Western blot produced under denaturing conditions. In comparison to the 
native Western blot, XApt002 failed to precipitate a sufficient amount of specific 
target to be detected. A large amount of protein may have bound non-specific 
during the AP using SVGp12 cell lysate.  
4.4.3 PDE1C specific aptamers in glioblastoma therapy 
Aptamers derived against PDE1C may need a vehicle in-order to deliver the ligand 
intracellular as this is where the protein target is localised. Previous studies have 
utilised aptamers to deliver interfering RNA intracellular, including small interfering 
RNA (siRNA) (Tan et al., 2012) and micro RNA (miRNA) (Esposito et al., 2014). It is 
therefore reasonable to suggest that aptamers could facilitate the delivery of 
conjugated aptamers intracellularly. Whilst this would help the aptamer gain access 
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to the target protein, the four aptamers selected have not been proven to have any 
inhibitory effects and further studies are required. 
4.5 Study limitations 
During this study, there was many limitations which were mostly caused by the lack 
of appropriate controls during experiments. Controls are important inclusions that 
ensure external factors do not obscure the variable being tested. 
4.5.1 Aptamer amplification via PCR 
DNA aptamers were amplified following each round of selection, using a pre-
determined optimal number of PCR cycles. A control was used whilst optimising the 
number of PCR cycles which lacked any Taq polymerase. The control showed that 
the eluted aptamers were indeed amplified, this was important as amplification 
showed that the SELEX selection may have been successful. Moreover, Taq 
polymerase has the ability to add an extra level of diversity to the aptamer pool. 
The enzyme lacks 3'-5' proof-reading and is therefore liable to error, approximately 
1 base in every 100,000 will be erroraneous. By adding more diversity to the 
aptamer pool, aptamers with better properties may be selected over time. 
A control lacking in PCR amplification experiments, previously outlined in Section 
was a PCR reaction lacking any template. This conventional control would have 
ensured the template being amplified was eluted aptamers, and not contamination. 
Although it is likely that contamination would have been noticeable, using both 
controls would have definitively shown that the 106bp aptamers were amplified. 
4.5.2 Aptamer-protein interaction via Western blots 
Several attempts were made throughout the course of this study to determine 
whether isolated aptamers bound to their intended target. Although methodologies 
to detect aptamer-PDE1C interaction and aptamer-EGFRvIII interaction were 
slightly different, the aim of the experiments were the same and both should have 
included similar controls which were not produced. 
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Negative controls should have been included during EGFRvIII aptamer validation 
(see Section 3.4.5). A negative control, in the absence of any aptamer, would have 
circumvented any doubts with respect to non-specific binding. Furthermore, if any 
binding was apparent, it would have served as bonified evidence that the aptamer 
is interaction with a protein contained in the cell lysate. 
Positive controls were lacking for both protein interaction experiments, these 
inclusions would have provided alot of information if produced. It could be 
concluded that the EGFRvIII aptamers did not bind any protein (see Section 3.4.5), 
however as a positive control was not produced, it cannot be ruled out that it was 
the experimental procedure combined with human error. Additionally, during the 
denaturing Western blot experiments to detect aptamer-PDE1C binding (see 
Section 3.5.4), if a positive control was introduced, using a commercially available 
antibody, more definitive conclusions could have been made. Whilst the size of a 
protein can not be deduced in non-denaturing conditions (see Section 3.5.4), a 
positive control using purified PDE1C protein would have shown where the PDE1C 
bands are on the PVDF membrane. By discovering where the known native protein 
was on the PVDF membrane, conclusions could have been made as to whether it 
aligned with the bands detected using the isolated aptamers. 
4.5.3 Aptamer-protein interaction via oligohistochemistry 
Paraffin embedded tissue, from the same sample used to create the short term 
cultures used within cell-SELEX, was utilised within oligohistochemistry in-order to 
determine whether the aptamers bound to a target on the cell surface. Whilst some 
staining was shown, there were inherent limitations within the experiment. 
Negative controls were lacking within this experiment. A negative control using 
non-cancerous tissue may have shown that the aptamer was specific to 
glioblastoma. Without this control, it could be argued that the staining shown was 
non-specific, caused by endogenous biotin within the cells. Nonetheless, this could 
have been avoided with the addition of a quenching step to block the background 
biotin, in contrast the same experiment could have been performed which lacked 
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the incubation of the aptamer with the tissue. This negative control would have 
highlighted the level of background biotin and qualitative observations could have 
been made on staining intensity. 
4.6 Future studies 
Aptamers have been attractive alternatives to antibodies ever since the early years 
of SELEX selection, as they have the ability to target disease with high specificity 
and high affinity. Nonetheless, before an aptamer may be utilised to its full 
potential, further studies are necessary in-order to determine binding 
characteristics, aptamer localisation and pharmacokinetic properties, amongst 
others. 
4.6.1 Establishing aptamer binding sites 
Aptamers are generally selected from large libraries of RNA or DNA 20-100 bases in 
length. A large number of sequence permutations will increase the chances of 
selecting an aptamer which efficiently binds to the target of choice. Although these 
targeting ligands have shown promise in the clinical setting, an issue is the cost of 
synthesising large sequences of DNA or RNA. For these reasons discovering which 
nucleotides are involved in binding is important, as not all nucleotides may be 
needed for the aptamer to bind to the target and in-turn, cut the cost of producing 
the targeting ligand in the clinical setting. 
Mutations can be introduced into aptamer sequences by site directed mutagenesis 
or by synthesising truncated aptamers (Huizenga and Szostak, 1995, Ruckman et al., 
1998), however where to introduce mutations may be difficult to determine as the 
length of the aptamer sequences become larger. Consensus sequence alignment 
between the aptamers, comparative to the alignments presented throughout this 
study, may help to determine where important motifs are although this may be 
inaccurate with small numbers of selected aptamers.    
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4.6.2 Establishing aptamer affinity towards protein epitope 
In the present study, 8 novel DNA aptamers have been identified towards 
glioblastoma cells and 14 aptamers have been targeted towards biomarkers 
important to gliomagenesis. The affinity these aptamers have towards the target 
however, is unknown. By establishing a disassociation constant (Kd), information to 
the aptamers affinity can be gained. In addition, aptamers that have multiple 
nucleotide positions that interact with the target have better Kd constants. This may 
be useful as it could provide information to further implicate a binding site. 
The Kd of aptamers derived towards whole cells may be investigated using flow 
cytometry. Cerchia et al., and Kang et al., were both successful in determining the 
disassociation constants of their aptamers by tagging the sequences with 
fluorescent compounds. By incubating the cells with various concentrations of 
fluorescently labelled aptamer, they were able to determine the aptamers Kd 
efficiently.  
Aptamers identified towards purified proteins already established to be of 
importance during gliomagenesis, may have their Kd constants checked using 
surface plasmon resonance (SPR), which detects refracted light emitted upon 
aptamer-protein interaction. Kaar and Yung used SPR to determine the Kd of 
VEGF165 specific aptamers (Kaur and Yung, 2012). Whilst this methodology may be 
effective in determine affinities to protein that are not membrane bound, affinities 
may be different when the protein is in its natural environment. Analysis by flow 
cytometry may provide more accurate information whether proteins are 
membrane bound and not free within the cytoplasm. 
4.6.3 Establishing aptamer target epitope 
Aptamers derived through cell-SELEX have the potential to identify novel 
biomarkers characteristic of disease, whilst simultaneously identifying a targeting 
ligand. The process uses a negative selection in the form of a whole cell with no or 
little pathological evidence of the disease, however no indications are given as to 
what the specific protein is (Sefah et al., 2010a). It is important to know the protein 
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which is targeted, mutated proteins may be exclusive to the disease, but over-
expressed proteins may be present in non-cancerous tissue. Further studies may be 
utilised, such as the aptoprecipitation protocol described in the present study, to 
isolate the target from native cell lysate which could be identified through mass 
spectrometry. 
4.6.4 Establishing aptamer localisation and enzymatic inhibition 
Novel DNA aptamers identified towards primary cells could be utilised for 
glioblastoma specific intracellular delivery of chemotherapeutics, with the aim of 
reducing therapy associated side effects that are not well tolerated in older patients 
(Brandes et al., 2008). The aptamer must be internalised within the cell for this 
potential to become reality and therefore, cellular localisation studies must be 
produced to show the aptamers are internalised efficiently. Aptamer localisation 
may be deduced by incubating the aptamer, tagged with a fluorophore, with live 
cells characteristic of the glioblastoma (Graham and Zarbl, 2012). Confocal 
microscopy of the cells, following aptamer incubation, will elucidate whether the 
aptamers are internalised or not. 
In this study, aptamers were selected towards PDE1C with the aim of producing a 
targeting ligand that would inhibit the enzymatic activity of the protein, which may 
reduce proliferative activity within glioblastoma tumours. Even though aptamers 
are well known to target active sites and therefore, induce inhibition (Section 
1.2.2), the PDE1C aptamers identified may interact with the protein without 
affecting function. An ELISA study could be produced to determine the rate at 
which the substrates, cAMP and cGMP, are catalytically changed to AMP and GMP 
(Gilbert et al., 2007). Decreased levels of the catalysed product will indicate an 
aptamer with inhibitory effects and may be used to decrease the activity of 
downstream mediators. 
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4.6.5 Enhancing the pharmacokinetic profile of aptamers 
The first therapeutic aptamer approved by the FDA, Pegaptanib, showed that the 
aptamer must be modified to increase the aptamer half-life within serum (Ruckman 
et al., 1998). Nucleases present within serum will degrade the oliognucleotides 
reducing the half-life of the aptamer, which could result in the aptamer failing to 
exert any therapeutic effects or deliver conjugated chemotherapies. To reduce 
nuclease degredation, individual nucleotides within the aptamer sequence may be 
modified at various positions (Fig 4.3). 
 
Figure 4.3 – Examples of nucleotide modifications to reduce degredation, increase half-
life and facilitate functionality.  Without intervention, aptamers will be degraded by 
nucleases within the serum. The half-life of administered aptamers may be increased 
following modifications, such as 2’fluoro or 2’O-methyl modifications. Aptamers may also 
be modified at the 3` end of the sequence using phosphorothioate dithiol linkages, in 
contrast the 5` end is normally reserved for conjugations to increase aptamer functionality. 
 
Although these modifications may reduce oligonucleotide degradation, aptamers 
be quickly filtered from the blood by renal filtration. Unmodified aptamers are 
generally 5-15 kDa, which is far below the threshold that would see the aptamer be 
retained within the circulating blood. Glomerular filtration will result in molecules 
being removed from the blood that are less than 30-40kDa (Ruggiero et al., 2010), 
however previous studies have utilised large moieties of polyethylene glycol or 
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cholesterol to limit aptamer excretion through the renal system (Rusconi et al., 
2004, Da Pieve et al., 2012). 
4.7 Conclusion 
A total of 22 novel DNA aptamers have been identified towards glioblastoma cells 
and purified proteins known to be important for gliomagenesis. Whilst validation 
studies have shown two aptamers derived using short-term cultures to interact 
with glioblastoma cells, more studies into the specificity and selectivity of the 
ligands are necessary to ensure the binding is specific. Aptamers targeted to 
EGFRvIII failed to show any interaction during validation studies when using the 
biotinylated sense sequence, further studies using the anti-sense aptamer 
sequence are required to determine whether this is the specific aptamer sequence. 
Validation studies using aptamers isolated towards PDE1C, by western blot and AP 
analyses, have shown the derived ligands to target a protein similar in molecular 
weight to PDE1C and its various isoforms. These aptamer sequences have the 
potential to target the protein; however whether they have inhibitory effects is still 
to be established. A cell-SELEX methodology was described, utilising TD-PCR and 
100 cells, one aptamer was sequenced following five rounds of cell-SELEX. Though 
this showed aptamers may be identified using a small number of cells, caution is 
advised as aptamers may be lost if too many iterative cycles are performed. The 
described procedure could potentially be used to select a panel of personalised 
aptamers to each patient following tumour biopsy. Excised tissue would need to be 
mapped to ensure the sample contains little non-cancerous tissue; however the 
time taken to test the aptamers could result in disease progression. Nevertheless, 
heterogenous cell populations will express varied biomarkers which can be utilised 
to provide personalised therapies and ultimately improve the outlook for 
glioblastoma patients. 
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Appendix : Miscallaenous aptamer sequences 
Appendix 1: Non-specifc PDE1C aptamer sequences 
4Forward: 
CCCTCGAGTTTACCGCAGAATTCATACCACTTGACCATGTTAATAAGCTATGCCCACCATAAG
TGACCTGACTGAATTCTCTCCCTATAGTGAGTCGTATTAGGAT 
4Reverse failed 
7Forward: 
ATCCTAATACGACTCACTATAGGGAGAATTCTGCGGTAAACTCGAGGG 
7Reverse failed 
8Forward failed 
8Reverse: 
ATCCTAATACGACTCACTATGGCCGGGCGGTGGAATTCTGCGGTAAACTCGAGGG 
9Forward: 
ATCCTAATACGACTCACTATGGCCACACGGAATTCTGCGGNNAACTCGAGGG 
9Reverse failed 
10Forward: 
CCCTCGAGTTTACCGCAGAATTCACCCCACAAGCCACACGCATCGATTGCCCGCCTATAGTGA
GTCGTATTAGGAT 
10Reverse: 
ATCCTAATACGACTCACTATAGGCGGGCAATCGATGCGTGTGGCTTGTGGGGTGAATTCTGC
GGTAAACTCGAGGG 
11Forward: 
ATCCTAATACGACTCACTATGCACAACCAGCCATGGGGAATTCTGCGGTAAACTCGAGGG 
11Reverse failed 
12Forward: 
CCCTCGAGTTTACCGCAGAATTCATGAGCTGACCGCGTACTGTGCCCGGTATAGTGAGTCGT
ATTAGGAT 
12Reverse: 
CCCTCGAGTTTACCGCAGAATTCGGCATGTCCCTCTGGCGGCATAGTGAGTCGTATTAGGAT 
13Forward: 
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CCCTCGAGTTTACCGCAGAATTCGGCATGTCCCTCTGGCGGCATAGTGAGTCGTATTAGGAT 
13Reverse failed 
14Forward: 
CCCTCGAGTTTACCGCAGAATTCGGCATGTCCCTCTGGCGGCATAGTGAGTCGTATTAGGAT 
14Reverse failed 
15Forward: 
ATCCTAATACGACTCACTATGCACCCGGACCGTACAGCGCTAGAATTCTGCGGTAAACTCGA
GGG 
15Reverse failed 
16Forward: 
CCCTCGAGTTTACCGCAGAATTCCCCCGCCCCCCGCCATAGTGAGTCGTATTAGGAT 
16Reverse: 
ATCCTAATACGACTCACTATGGCGGGGGGCGGGGGAATTCTGCGGTAAACTCGAGGG 
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